On this page
Quick Reference
Overview and Recommendations
Background
- •Identify SIADH as the leading cause of euvolemic , often triggered by ectopic AVP production or enhanced hypothalamic release.
- •Recognize (SCLC) as the most common paraneoplastic association, occurring in up to 15-45% of cases.
- •Screen for neurological triggers including , , and post-pituitary surgery.
- •Review medication history for common culprits: (SSRIs), , , and .
- •Distinguish from (CSW), which presents with similar biochemistry but involves true volume depletion (hypovolemia).
Evaluation
- •Confirm hypotonic hyponatremia: Serum sodium <135 mmol/L and serum osmolality <275 mOsm/kg.
- •Obtain urine osmolality: A value >100 mOsm/kg indicates inappropriately concentrated urine in the setting of serum hypotonicity.
- •Measure urinary sodium: Concentration >30-40 mmol/L is typical during normal salt and water intake.
- •Assess volume status: Confirm clinical by the absence of edema, ascites, or signs of dehydration (e.g., orthostasis).
- •Rule out mimics: Obtain TSH and morning cortisol to exclude and .
- •Calculate Fractional Excretion of Uric Acid (FEurate): A value >12% supports SIADH; normalization after sodium correction confirms the diagnosis.
- •Utilize as a surrogate marker for AVP if the diagnosis remains ambiguous.
Management
- •Administer Hypertonic Saline (3% NaCl) 100-150 mL IV bolus over 10-20 minutes for severe symptoms (seizures, coma, or severe confusion).
- •Limit correction rate: Avoid increasing serum sodium by >8-10 mmol/L in 24 hours to prevent (ODS).
- •Implement Fluid Restriction <800-1000 mL/day as the first-line intervention for asymptomatic or mildly symptomatic patients.
- •Consider 7.5-15 mg PO daily for patients failing fluid restriction; monitor sodium closely every 6-8 hours during initiation.
- •Prescribe oral Urea 15-30 g/day to induce osmotic diuresis in chronic or refractory cases.
- •Avoid 0.9% Normal Saline: This may paradoxically worsen hyponatremia via the 'desalination' phenomenon if urine osmolality is high.
- •Treat the underlying cause: Discontinue offending medications or initiate therapy for the primary malignancy or infection.
Board Review — High Yield
- •Small Cell Lung Cancer — The classic paraneoplastic cause of SIADH due to ectopic AVP production.
- •Euvolemia — The hallmark physical exam finding; patients lack both edema and signs of dehydration.
- •Urine Osmolality >100 mOsm/kg — Inappropriately high concentration despite low serum osmolality (<275 mOsm/kg).
- •Osmotic Demyelination Syndrome — A permanent neurological injury caused by correcting chronic hyponatremia too rapidly.
- •Desalination — Paradoxical worsening of hyponatremia after giving isotonic saline because the kidney excretes the salt but keeps the water.
- •Fractional Excretion of Uric Acid >12% — A high FEurate in a hyponatremic patient is highly suggestive of SIADH.
- •SSRIs — The most common class of medications associated with drug-induced SIADH, especially in the elderly.
- •V2 Receptor Antagonists — The mechanism of action for 'vaptans' like Tolvaptan, which block AVP-mediated water reabsorption.
Deep Dive — Evidence Details
Definition and Components
- ▸SIADH is defined by euvolemic hypotonic hyponatremia with inappropriately concentrated urine (U-Osm >100 mOsm/kg).
- ▸The syndrome requires the exclusion of renal, adrenal, and thyroid insufficiency to confirm the 'inappropriate' nature of AVP secretion.
- ▸Copeptin serves as a stable surrogate marker for AVP, remaining elevated in SIADH despite low serum osmolality.
The Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH), also referred to as the Syndrome of Inappropriate Antidiuresis (SIAD), is a clinical disorder of water balance characterized by the non-physiological release of (AVP) or an enhanced sensitivity to it [2]D[12]D. This leads to impaired free-water excretion and the development of euvolemic [4]D[15]D. SIADH is recognized as the most prevalent cause of hyponatremia in hospitalized patients, though it is often under-recognized or inappropriately managed [13]D[15]D.
Historical Context and Diagnostic Framework
The clinical definition of SIADH is traditionally based on the Schwartz and Bartter criteria, which emphasize the "inappropriate" nature of antidiuresis in the absence of physiological stimuli for AVP release, such as hypotension or hyperosmolality [15]D. In a healthy state, plasma tonicity is defended by AVP and the thirst response, while volume is maintained via the renin-angiotensin-aldosterone axis [2]D. In SIADH, this balance is disrupted, leading to water retention that is disproportionate to the body's exchangeable sodium and potassium levels [2]D.
Core Components of SIADH
The diagnosis of SIADH requires the fulfillment of several biochemical and clinical components:
- Hypotonic Hyponatremia: A serum sodium <135 mmol/L (or <136 mmol/L in some labs) accompanied by a serum osmolality <275 mOsm/kg [1][11]D[15]D.
- Inappropriate Urine Concentration: A urine osmolality >100 mOsm/kg despite low serum osmolality [15]D.
- Elevated Urinary Sodium: A urinary sodium concentration >30 mmol/L (often >40 mmol/L) while on a normal salt and water intake [11]D[15]D.
- Clinical Euvolemia: The absence of clinical signs of volume depletion (e.g., orthostasis, dry mucous membranes) or volume excess (e.g., edema, ascites) [15]D.
- Exclusion of Mimics: Normal thyroid and adrenal function must be confirmed, as deficiencies in these axes (e.g., pituitary insufficiency) can stimulate AVP and mimic SIADH [7]D[15]D.
Pathophysiology of Components
The primary defect in SIADH is the failure of the kidneys to dilute urine due to the persistent action of AVP on the V2 receptors in the collecting ducts [4]D. Recent research has utilized copeptin, the C-terminal fragment of the AVP precursor, as a stable surrogate marker for AVP secretion [6]D[12]D. Copeptin levels correlate closely with serum osmolality in healthy individuals, with a mean osmotic threshold of 282 ± 4 mOsm/kg [12]D. In SIADH, copeptin levels remain inappropriately elevated relative to the low serum osmolality [6]D[12]D.
Etiology and Associated Conditions
SIADH is associated with a wide array of triggers, ranging from neurological insults to pharmacological agents.
| Category | Specific Causes and Triggers |
|---|---|
| Neurological Disorders | [11]D, [9]D, brain tumors [14]D, and neurosurgical procedures [2]D. |
| Pituitary Pathology | Pituitary surgery (endoscopic transsphenoidal surgery) [8]C[10]D, pituitary apoplexy [16]D, and pituitary insufficiency [7]D. |
| Pharmacological Agents | (SSRIs) [1], antipsychotics [1], antiepileptics [1], and proton pump inhibitors (PPIs) [17]D. |
| Drug Interactions | Combination of vincristine with azole antifungals (itraconazole, posaconazole, voriconazole, ketoconazole) [3]D. |
| Systemic Conditions | Cushing disease (post-operative) [8]C and various malignancies [14]D. |
Differential Components
It is critical to distinguish SIADH from other forms of hyponatremia. In patients with cirrhosis, hyponatremia is typically hypervolemic (associated with ascites and edema) or hypovolemic (due to diuretics), rather than euvolemic [5]D. Furthermore, Cerebral Salt Wasting (CSW), often seen after aneurysmal subarachnoid hemorrhage, presents with hyponatremia and high urine output (>4 L in 12 hours), but unlike SIADH, it involves true volume depletion [11]D. Fractional excretion of uric acid can also assist in differentiation, particularly in patients on diuretics where standard urinary sodium measurements are unreliable [15]D.
| Category | Causes Mentioned in Literature |
|---|---|
| Medications | SSRIs, Antipsychotics, Antiepileptics, PPIs (Omeprazole), Vincristine [1][3]D[17]D |
| Neurological | Neurosurgery, SAH, GBS, Brain tumors, Pituitary apoplexy [2]D[9]D[11]D[14]D[16]D |
| Surgical/Endocrine | Transsphenoidal surgery, Cushing disease, Pituitary insufficiency [7]D[8]C[10]D |
Epidemiology and Risk Factors
- ▸SIADH is the leading cause of hyponatremia in hospitalized patients, with a prevalence of 27% in general wards.
- ▸Post-transsphenoidal surgery patients face a high risk (9%–30.7%) of delayed SIADH, typically peaking around postoperative day 8.
- ▸Small cell lung cancer remains the most significant oncological risk factor, with an SIADH incidence of nearly 19%.
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most common cause of in hospitalized patients [29][30]. Its prevalence varies significantly depending on the underlying clinical context, ranging from transient postoperative states to chronic paraneoplastic manifestations [21][44]D.
General Prevalence
In general medical wards, SIADH accounts for approximately 27% of hyponatremic cases [47]D. However, in specific populations such as those with , the prevalence of hyponatremia (largely driven by SIADH) can range from 3% to 94.8%, with an average of 15% to 45% depending on the histological subtype [21][45]D. Small cell lung cancer (SCLC) exhibits a particularly high association, with SIADH occurring in up to 18.9% of patients [45]D.
Risk Factors by Clinical Category
Malignancy
SIADH is a well-recognized paraneoplastic syndrome. While SCLC is the most frequent cause, several other malignancies are associated with ectopic ADH production:
- Olfactory Neuroblastoma (ONB): Ectopic ONB (originating outside the olfactory cleft) is associated with a higher frequency of SIADH compared to orthotopic tumors [19]. Among nasal and paranasal malignant tumors, ONB has an SIADH incidence of 15.4% [33]D.
- Neuroendocrine Tumors: Including mediastinal neuroblastoma in elderly patients [42]C and other neuroendocrine carcinomas (11.1% incidence) [33]D.
- Other Respiratory Cancers: Squamous cell carcinoma of the head and neck (1.6%) and lung adenocarcinoma [26]C[33]D.
Neurosurgical and Neurological Conditions
Postoperative hyponatremia is a major complication of skull base and pituitary surgeries.
- Transsphenoidal Surgery (TSS): The incidence of delayed hyponatremia following TSS for pituitary adenomas ranges from 9% to 30.7% [18][22]. Symptomatic patients typically present an average of 8.6 days post-surgery [37]D. Risk factors for SIADH after TSS include female sex and specific tumor pathologies [44]D.
- Traumatic Brain Injury (TBI): SIADH is a frequent determinant of hyponatremia in TBI patients, contributing to increased morbidity and prolonged hospital stays [40]D.
- Cerebrovascular Events: SIADH is the most common cause of hyponatremia in patients with acute [27]. It is also a frequent complication following aneurysmal subarachnoid hemorrhage (aSAH) [36]D.
- Autoimmune Disorders: Approximately 12% of patients with neuromyelitis optica spectrum disorder (NMOSD) experience SIADH [35]D.
Pharmacological Triggers
Numerous medications can induce SIADH by either stimulating ADH release or enhancing renal sensitivity to ADH.
- Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine 20 mg QD, paroxetine 20 mg QD, sertraline 50 mg QD, citalopram 20 mg QD, and escitalopram 10 mg QD are strongly associated with SIADH, particularly in elderly patients [30][32]D. Serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine 60 mg QD and venlafaxine 75 mg QD also carry significant risk [32]D. Mirtazapine is considered a potential alternative with a lower, though not absent, risk [30].
- Antineoplastic Agents: The tyrosine kinase inhibitor osimertinib 80 mg QD has been reported to induce SIADH in patients with EGFR-mutated lung adenocarcinoma [26]C.
- Other Agents: Psychotropic medications in patients with Prader-Willi Syndrome [43]D and desmopressin (when used for diabetes insipidus) can lead to dilutional hyponatremia mimicking SIADH [46]D. Conversely, lithium therapy is associated with a reduced risk of hyponatremia due to its potential to induce nephrogenic diabetes insipidus [25].
Infectious Diseases
- COVID-19: SIADH is a recognized mechanism for hyponatremia in patients with SARS-CoV-2 infection [28][46]D.
- Brucellosis: Systematic reviews have identified SIADH as a complication of brucellosis infection [29].
- Respiratory Syncytial Virus (RSV): SIADH-induced hyponatremia has been noted in severe RSV cases and may be associated with the development of Guillain-Barré syndrome [31]D.
Demographic and Genetic Factors
- Age: Elderly patients (>65 years) are at higher risk, particularly when prescribed SSRIs or following RSV infection [30][31]D.
- Prader-Willi Syndrome (PWS): Approximately 2.6% of patients with PWS experience hyponatremia, often due to a combination of SIADH from psychotropic use and excessive fluid intake [43]D.
- Alzheimer's Disease: While hyponatremia is common, recent evidence suggests many cases previously attributed to SIADH may actually be renal salt wasting (RSW) [34]D.
| Condition | Reported Incidence/Prevalence | Reference |
|---|---|---|
| Small Cell Lung Cancer (SCLC) | Up to 18.9% | [45]D |
| Lung Cancer (All types) | 3% – 94.8% (Average 15-45%) | [21] |
| Transsphenoidal Surgery (TSS) | 9% – 30.7% | [18][22] |
| Olfactory Neuroblastoma | 15.4% | [33]D |
| Neuromyelitis Optica (NMOSD) | 12% | [35]D |
| Nasal/Paranasal Malignancy | 3.2% | [33]D |
| Prader-Willi Syndrome | 2.6% | [43]D |
| Drug Class | Specific Agents | Risk Context |
|---|---|---|
| SSRIs | Fluoxetine, Paroxetine, Sertraline, Citalopram, Escitalopram | High risk in elderly [30][32]D |
| SNRIs | Duloxetine, Venlafaxine | Significant risk [32]D |
| TKI | Osimertinib | EGFR-mutated NSCLC [26]C |
| Tetracyclic | Mirtazapine | Lower risk than SSRIs [30] |
| Antimanic | Lithium | Protective (reduces risk) [25] |
Etiology
- ▸SIADH is primarily driven by nonosmotic arginine vasopressin (AVP) release or constitutive V2 receptor activation.
- ▸Small cell lung cancer (SCLC) and traumatic brain injury (TBI) are the most common malignant and neurogenic triggers, respectively.
- ▸Drug-induced SIADH is a major concern in elderly populations, particularly with SSRI and SNRI use.
The syndrome of inappropriate antidiuresis (SIAD) is the most frequent cause of hypotonic [54]D. It is primarily mediated by the nonosmotic release of arginine vasopressin (AVP), which activates renal vasopressin type 2 (V2) receptors and promotes water retention [54]D. The etiologies of SIADH are diverse, encompassing malignancies, central nervous system (CNS) disorders, pulmonary diseases, medications, and genetic mutations [54]D.
Malignancy
Malignant tumors are a classic cause of SIADH, often through ectopic production of AVP [54]D. Small cell lung cancer (SCLC) is the most common associated malignancy [52]C[54]D. Rare neuroendocrine tumors, such as olfactory neuroblastoma (both orthotopic and ectopic) and thymic neuroblastoma, are also linked to paraneoplastic SIADH [19][58]C. Molecular alterations, such as gain of copies of the PIK3CA gene, have been identified in thymic neuroblastoma cases [58]C.
Central Nervous System Disorders
CNS insults can disrupt the hypothalamic-pituitary axis, leading to unregulated AVP secretion [50][54]D. Traumatic brain injury (TBI) is a frequent trigger, with hyponatremia occurring in 20-50% of cases [60]C. While often transient, TBI-induced SIADH can persist for years or recur [60]C[62]C. Other neurogenic causes include subarachnoid hemorrhage, brain tumors, and normal pressure hydrocephalus (NPH), where a lumbar puncture may resolve the hyponatremia [50][59]C.
Medications
Drug-induced SIADH is common, particularly in elderly patients [53]D[68]D. For every 1-year increase in age, serum sodium levels in hyponatremic patients decrease by 0.14 mmol/L [68]D. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are frequently implicated [32]D[53]D.
Post-Surgical and Medical Procedures
Manipulation of the posterior pituitary gland during neurosurgery is a significant risk factor [70]D. Transsphenoidal surgery for sellar lesions, such as pituitary adenomas or craniopharyngiomas, frequently results in postoperative hyponatremia [18][24][49]. Additionally, SIADH has been reported following hematopoietic stem cell transplantation, sometimes associated with pre-engraftment syndrome [71]C.
Genetic and Metabolic Disorders
Rare germline mutations can cause nephrogenic syndrome of inappropriate antidiuresis (NSIAD) [54]D[67]D. These include activating mutations of the V2 receptor or germline-derived GNAS-Gsα variants [54]D[67]D. Metabolic triggers include hereditary tyrosinemia type 1 (HT1), where accumulation of succinylacetone leads to porphyria-like neurovisceral crises and inappropriately increased copeptin [57]C[65]C. Thiamine deficiency causing Wernicke encephalopathy has also been documented as a trigger [61]C.
| Category | Specific Causes |
|---|---|
| Malignancies | Small cell lung cancer (SCLC) [52]C[54]D, Olfactory neuroblastoma [19], Thymic neuroblastoma [58]C, Pituitary adenoma [49][18], Craniopharyngioma [24][64]D, Chordoma [24], Brain tumors [50] |
| CNS Disorders | Traumatic brain injury (TBI) [50][55]C[60]C, Subarachnoid hemorrhage [50], Normal pressure hydrocephalus (NPH) [59]C, Multiple system atrophy (MSA) [56]C, Wernicke encephalopathy [61]C, VZV meningoencephalitis [69]C, Guillain-Barre Syndrome (GBS) [72]C, Posterior reversible encephalopathy syndrome (PRES) [72]C |
| Pulmonary | Pneumonia [54]D, General pulmonary diseases [54]D |
| Drug Class | Examples and Reported Doses |
|---|---|
| SSRIs | Fluoxetine, Paroxetine, Sertraline, Citalopram, Escitalopram [32]D[53]D |
| SNRIs | Duloxetine (e.g., 30 mg/day), Venlafaxine [32]D[53]D[56]C |
| Antiepileptics | Carbamazepine [53]D |
| Antineoplastics | Cyclophosphamide [53]D |
| Antipsychotics | Olanzapine [60]C |
| Other | Bupropion (NRI) [32]D, Omeprazole [32]D |
Pathophysiology
- ▸SIADH is mediated by nonosmotic AVP release or V2 receptor activation, leading to aquaporin-2 translocation and excessive renal water reabsorption.
- ▸Euvolemia is maintained through secondary natriuresis and 'vasopressin escape,' which prevents overt edema but worsens hyponatremia.
- ▸Copeptin serves as a stable, equimolar surrogate biomarker for AVP secretion in the diagnosis of SIAD subtypes.
The fundamental defect in the syndrome of inappropriate antidiuresis (SIAD) is the nonosmotic release of (AVP), previously known as antidiuretic hormone [54]D[77]D. Under normal physiological conditions, AVP secretion from the posterior pituitary is suppressed when plasma osmolality falls below a threshold of approximately 280 mOsm/kg. In SIADH, AVP secretion persists despite low plasma osmolality and normal or increased effective circulating volume [77]D[95]D.
Molecular Mechanism of Water Retention
AVP exerts its primary effect by binding to the vasopressin type 2 (V2) receptors located on the basolateral membrane of principal cells in the renal collecting ducts [54]D[99]D. This binding activates adenylyl cyclase, increasing intracellular cyclic AMP, which triggers the translocation of water channels from intracellular vesicles to the apical (luminal) membrane [99]D. This process significantly increases the water permeability of the collecting duct, allowing for excessive free water reabsorption along the osmotic gradient into the renal interstitium [80]D[99]D. The result is the production of inappropriately concentrated urine and a decrease in plasma sodium concentration [80]D[97]C.
Maintenance of Euvolemia and Natriuresis
SIADH is the most common cause of euvolemic Hyponatremia [74][95]D. The initial water retention leads to a modest expansion of the extracellular fluid (ECF) volume [95]D[97]C. This expansion triggers secondary physiological responses to maintain volume homeostasis:
- RAAS Suppression: Increased ECF volume suppresses the renin-angiotensin-aldosterone system, reducing sodium reabsorption [54]D[77]D.
- Natriuretic Peptide Release: Volume expansion stimulates the release of atrial and brain natriuretic peptides [77]D.
- Natriuresis: These factors promote urinary sodium excretion ( ), which returns ECF volume toward normal (euvolemia) but at the cost of further lowering serum sodium levels [77]D[95]D.
- Vasopressin Escape: To prevent progressive volume expansion, the kidneys eventually downregulate aquaporin-2 expression despite high AVP levels, a phenomenon known as "vasopressin escape" [54]D[77]D.
Acid-Base and Cellular Dynamics
Despite significant reductions in serum sodium and chloride, patients with SIADH typically maintain normal serum bicarbonate concentrations and systemic acid-base homeostasis [75]D. The renal molecular mechanisms preserving this balance are distinct from those regulating sodium [75]D. At the cellular level, acute hypoosmolality causes rapid water uptake and swelling in astrocytes because they express functional aquaporins [93]D. In contrast, neurons lack functional aquaporins and do not swell as a direct osmotic consequence of low plasma osmolality, though they may swell due to other factors like ischemia or spreading depolarization [93]D.
Biomarkers and Genetic Variants
is the C-terminal part of the AVP precursor and is released in equimolar amounts with AVP from the posterior pituitary [76]D[80]D. Because it is more stable in the blood and easier to analyze, it serves as a reliable surrogate biomarker for AVP secretion in endocrine disorders [76]D[80]D[87]C.
Rarely, SIAD occurs without elevated AVP levels. Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) is caused by gain-of-function mutations in the V2 receptor, leading to constitutive activation and water retention even when AVP is undetectable [54]D[79]D. Another variant, Reset Osmostat, involves osmoreceptors that function normally but are set to a lower-than-normal threshold for AVP release [79]D.
Novel Pathophysiological Factors
Recent research suggests that may stimulate AVP secretion [83]D. This can occur through direct ingestion or endogenous production via the polyol pathway, potentially contributing to SIADH and exercise-associated hyponatremia in marathon runners [83]D.
| Category | Specific Causes and Conditions |
|---|---|
| Malignancy | Lung cancer [75]D, Anterior mediastinal neuroblastoma [42]C, Prostate cancer [82]C, Breast cancer [97]C |
| CNS Disorders | Traumatic brain injury (TBI) [55]C, Brain tumors [75]D, Hypothalamic diseases [75]D, Pituitary surgery/Transsphenoidal surgery [89]D[91]D[98]D, Hypothalamic hamartoma [87]C[92]C, Corpus callosum agenesis [99]D, Posterior pituitary micronodular formation [86]C, Tuberculous meningitis [90]D |
| Pulmonary | Pneumonia [75]D[99]D, Respiratory syncytial virus (RSV) [94]C |
| Medications | Linezolid [96]C, Cyclophosphamide [97]C, Doxorubicin [97]C, Ketamine [82]C, Hyponatraemia-inducing medications (HIMs) [84]D |
| Infections | Varicella [81]C, Tuberculous meningitis [90]D, RSV [94]C |
| Genetic/Other | V2 receptor activating mutations (NSIAD) [54]D[79]D, Reset osmostat [79]D, Eosinophilic granulomatosis with polyangiitis (EGPA) [78]C, Fructose ingestion/Polyol pathway activation [83]D, Exercise-associated (marathon running) [83]D, Solitary central incisor/Neurofibromatosis-1 [88]C, Pain [99]D, Postoperative state [99]D |
Clinical Features
- ▸Clinical euvolemia is the hallmark physical finding of SIADH, characterized by the absence of both edema and signs of dehydration [111, 121].
- ▸Neurological symptom severity depends more on the rate of sodium decline than the absolute concentration; acute drops lead to cerebral edema and herniation [101, 104].
- ▸Chronic mild hyponatremia in the elderly is a major risk factor for cognitive decline, gait instability, and bone fractures [101].
The clinical presentation of the syndrome of inappropriate antidiuretic hormone (SIADH) spans a broad spectrum, ranging from entirely asymptomatic cases to life-threatening neurological emergencies [101]D[116]C. The severity of symptoms is primarily determined by the rapidity of the decline in serum sodium, the duration of the electrolyte imbalance, and the absolute degree of , which is defined as a serum sodium level <135 mEq/L [101]D[112]C.
Physical Examination: The Euvolemic State
A defining clinical feature of SIADH is the presence of clinical [111]D[121]C. On physical examination, clinicians typically find no evidence of extracellular fluid volume depletion or excess [111]D.
- Absence of Dehydration: Patients lack signs such as dry mucous membranes, decreased skin turgor, or orthostatic hypotension [121]C.
- Absence of Overload: Despite water retention, patients do not typically exhibit peripheral edema, ascites, or pulmonary rales [111]D.
- Compensatory Natriuresis: The expansion of extracellular fluid volume is usually insufficient to cause hypertension because the body compensates by increasing urinary sodium excretion [111]D.
Neurological Manifestations
Neurological symptoms are the most prominent features of SIADH, resulting from an osmotic shift of water into brain cells that causes [104]C[113]C.
Mild to Moderate Symptoms
Early or chronic hyponatremia often presents with nonspecific symptoms, including nausea, anorexia, malaise, and generalized weakness [82]C[101]D[121]C. Patients may also report dizziness, fatigue, and abdominal bloating [82]C[102]C. Cognitive and behavioral changes are common, including impaired concentration, inattentiveness, and delirium [112]C[123]C. Rare but documented symptoms include persistent hiccups and suicidal ideation [123]C.
Severe and Acute Symptoms
When serum sodium drops rapidly, acute may develop [113]C[119]C. This is characterized by a severely impaired level of consciousness, , and diffuse cerebral edema visible on imaging [113]C[121]C. If the hyponatremia is not corrected, it can progress to , coma, and fatal brain herniation [101]D[104]C[114]C. Some patients may also exhibit photophobia (hypersensitivity to light), ocular pain, and lower limb weakness [114]C.
Features in Specific Populations
- Elderly Patients: In older adults, even mild chronic hyponatremia is associated with significant morbidity, including cognitive impairment and gait disturbances [101]D. This population has a markedly increased risk of falls and fractures [101]D. Asymptomatic presentations are common in the elderly, even with sodium levels as low as 108–110 mmol/L, though these patients remain at high risk for sudden decompensation [116]C.
- Infants and Neonates: Infants with SIADH often present with life-threatening seizures and irritability [87]C[119]C. Neonates born to mothers with hyponatremia during labor may present with similarly low sodium levels and respiratory distress [120]C.
- Post-Surgical Patients: Patients undergoing pituitary surgery or spinal decompression may develop SIADH postoperatively, presenting with nausea, vomiting, and impaired consciousness [107]D[117]D[121]C.
Associated Systemic Findings
- Musculoskeletal: Severe SIADH has been associated with , particularly when it occurs alongside neuroleptic malignant syndrome or certain intoxications (e.g., Boswellia serrata 1000mg/d) [104]C[114]C.
- Thermoregulation: While SIADH itself is not pyrogenic, patients with hypothalamic involvement (e.g., multiple system atrophy or neuromyelitis optica) may present with high fevers (38.0–39.5 °C) alongside hyponatremia [56]C[122]C.
- Autonomic and Pain Symptoms: In cases secondary to acute intermittent porphyria, SIADH may be accompanied by recurrent abdominal, chest, or back pain, as well as rash and arthralgia [105]C. In Guillain-Barré syndrome, it may coexist with [118]D.
| Severity | Serum Sodium (mEq/L) | Common Clinical Features |
|---|---|---|
| Mild | 130–134 | Fatigue, weakness, nausea, cognitive slowing, gait instability [101]D[102]C |
| Moderate | 120–129 | Malaise, headache, confusion, lethargy, ataxia, hiccups [82]C[113]C[123]C |
| Severe | <120 | Seizures, coma, cerebral edema, rhabdomyolysis, respiratory arrest [101]D[104]C[119]C |
Diagnostic Criteria
- ▸SIADH is a diagnosis of exclusion requiring confirmed hypotonic hyponatremia, inappropriate urine concentration (>100 mOsm/kg), and clinical euvolemia.
- ▸Fractional excretion of uric acid (FEurate) >12% is a critical supplemental marker to distinguish SIADH from other hyponatremic states.
- ▸The absence of adrenal, thyroid, and renal dysfunction, as well as the absence of diuretic use, is mandatory for a definitive diagnosis.
The diagnosis of the (SIADH) is primarily clinical and biochemical, requiring the exclusion of other causes of hypotonic hyponatremia [126]D, [128]C. It is characterized by the non-physiological secretion of arginine vasopressin (AVP), leading to water retention and dilutional hyponatremia despite normal or increased plasma volume [79]D, [130]C.
Essential Diagnostic Criteria
To confirm a diagnosis of SIADH, the following essential criteria must be met [33]D, [126]D:
- Hypotonic hyponatremia: Serum sodium <135 mmol/L and effective serum osmolality <275 mOsm/kg [126]D.
- Inappropriate urine concentration: Urine osmolality >100 mOsm/kg during the state of hypotonicity [33]D, [126]D.
- Clinical euvolemia: Absence of clinical signs of volume depletion (e.g., orthostatic hypotension, dry mucous membranes, decreased skin turgor) or volume excess (e.g., peripheral edema, ascites, pulmonary congestion) [57]C, [79]D.
- Elevated urinary sodium: Urine sodium concentration >30 mmol/L (often >40 mmol/L) while on a normal salt and water intake [126]D.
- Exclusion of alternative etiologies: Normal thyroid function (TSH), normal adrenal function (cortisol), and absence of diuretic use (particularly thiazides) [129]C, [135]D.
Supplemental and Advanced Laboratory Markers
When the diagnosis is ambiguous, particularly in differentiating SIADH from (CSW), supplemental markers are utilized [50], [126]D.
- Fractional Excretion of Uric Acid (FEurate): A FEurate >12% is highly suggestive of SIADH in a hyponatremic patient [50], [126]D. If the FEurate remains elevated after the correction of hyponatremia, it may suggest CSW, whereas it typically normalizes in SIADH [50].
- Serum Uric Acid: Hypouricemia (serum uric acid <4 mg/dL) is common due to increased urate clearance [68]D.
- Blood Urea Nitrogen (BUN): Typically low (<10 mg/dL) due to volume expansion and increased urea clearance [126]D.
- Fractional Excretion of Phosphate (FEphosphate): A FEphosphate >20% has been used in pediatric populations to support the diagnosis [50].
- Plasma Copeptin: Copeptin is the C-terminal fragment of the AVP precursor. Elevated levels in the setting of hypotonicity can serve as a surrogate marker for inappropriate AVP secretion [57]C, [130]C.
- Saline Infusion Test: Failure of the serum sodium to increase significantly after the administration of 1–2 liters of isotonic saline (0.9% NaCl) supports SIADH over hypovolemic hyponatremia [79]D.
Differential Diagnosis and Subtypes
SIADH must be distinguished from other euvolemic or near-euvolemic states [79]D, [135]D.
| Feature | SIADH | Cerebral Salt Wasting (CSW) | Thiazide-Induced Hyponatremia |
|---|---|---|---|
| Volume Status | Euvolemic | Hypovolemic | Euvolemic or Hypovolemic |
| Urine Sodium | >30 mmol/L | >40-100 mmol/L | Variable |
| Serum Uric Acid | Low (<4 mg/dL) | Low | Variable |
| FEurate | >12% | >12% | Variable [135]D |
| Response to Fluid Restriction | Sodium increases | Sodium decreases/No change | Sodium increases |
| Response to Saline | Sodium decreases/No change | Sodium increases | Sodium increases |
Variant Syndromes
- Reset Osmostat: A subtype where AVP is secreted normally but the threshold for secretion is set at a lower serum osmolality. Patients maintain a stable but low serum sodium [79]D.
- Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD): A genetic condition caused by gain-of-function mutations in the V2 receptor. Clinical presentation is identical to SIADH, but AVP/copeptin levels are suppressed [79]D.
Clinical Contexts Requiring High Suspicion
Diagnostic evaluation should be triggered in specific clinical scenarios associated with SIADH:
- Malignancy: Particularly (SCLC) [130]C and nasal/paranasal tumors like [19], [33]D, [129]C.
- Neurological Disorders: Including (NMOSD) [102]C, [133]C, [61]C, and Normal Pressure Hydrocephalus [59]C.
- Post-Surgical States: Especially following transsphenoidal pituitary surgery [20], [49], [70]D, [132]D.
- Infectious/Metabolic: COVID-19 infection [109]D, [131]C and Hereditary Tyrosinemia Type 1 [57]C, [65]C.
| Parameter | SIADH | CSW | Reset Osmostat |
|---|---|---|---|
| Serum Osmolality | <275 mOsm/kg | <275 mOsm/kg | <275 mOsm/kg |
| Urine Osmolality | >100 mOsm/kg | >100 mOsm/kg | Variable |
| Urine Sodium | >30 mmol/L | >40 mmol/L | Variable |
| Volume Status | Euvolemic | Hypovolemic | Euvolemic |
| FEurate | >12% | >12% | Normal |
Workup and Laboratory Findings
- ▸SIADH is characterized by the triad of hypotonic hyponatremia, inappropriately concentrated urine (Uosm >100 mOsm/kg), and elevated urine sodium (>40 mmol/L) in a euvolemic patient.
- ▸Fractional excretion of uric acid (FEurate) >12% is a highly sensitive marker for SIADH and helps distinguish it from other hyponatremic states.
- ▸Copeptin serves as a stable surrogate for ADH and is increasingly used to confirm the diagnosis in complex or refractory cases.
The diagnosis of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) requires a systematic laboratory evaluation to confirm hypotonic hyponatremia in the setting of clinical euvolemia [138]D[151]D. Because SIADH is a diagnosis of exclusion, clinicians must first rule out renal, adrenal, and thyroid dysfunction [52]C[141]C. The workup focuses on assessing serum and urine osmolality, electrolyte concentrations, and specialized markers like uric acid and copeptin [6]D[148]C.
Primary Diagnostic Criteria
Standardized criteria for SIADH diagnosis include the following laboratory findings [52]C[138]D[151]D:
- Serum Sodium <135 mmol/L: Severe cases may present with levels <120 mmol/L or even <100 mmol/L [139]C[144]C.
- Serum Osmolality <275 mOsm/kg: Confirms true hypotonicity [56]C[149]C.
- Urine Osmolality >100 mOsm/kg: Indicates inappropriately concentrated urine despite serum hypoosmolality [56]C[149]C.
- Urine Sodium >40 mmol/L: Reflects persistent natriuresis despite hyponatremia, provided the patient is on a normal salt and water intake [52]C[151]D.
- Clinical Euvolemia: Absence of signs of hypovolemia (e.g., orthostasis, dry mucous membranes) or hypervolemia (e.g., edema, ascites) [151]D.
Serum and Urine Analysis
Uric Acid and Fractional Excretions
Hypouricemia (Serum Uric Acid <4 mg/dL or <238 µmol/L) is a hallmark of SIADH due to increased urate clearance [139]C[148]C. Measuring the fractional excretion of uric acid (FEurate) and phosphate (FEphosphate) is critical for differentiating SIADH from other neurogenic causes of hyponatremia [50][148]C.
- FEurate: Typically >12% in SIADH. A high FEurate that normalizes after hyponatremia correction suggests SIADH, whereas a persistently high FEurate despite correction may indicate (CSW) [50][148]C.
- FEphosphate: Elevated in SIADH and CSW, aiding in the exclusion of simple hypovolemic hyponatremia [50].
The Desalination Phenomenon
In some cases of SIADH, the administration of isotonic saline (0.9% NaCl) may lead to a paradoxical decrease in serum sodium, known as the "desalination phenomenon" [139]C. This occurs when the kidneys excrete the administered sodium in a small volume of concentrated urine while retaining the free water, further worsening the hyponatremia [139]C.
Advanced Biomarkers
Copeptin
Copeptin, the C-terminal segment of the arginine vasopressin (AVP) precursor, serves as a stable surrogate marker for ADH [6]D.
- Diagnostic Utility: Elevated copeptin levels in the presence of hyponatremia and low serum osmolality support a diagnosis of SIADH [6]D.
- Delta Copeptin: Recent studies in pediatric populations suggest that the change in copeptin levels (Delta Copeptin) following a fluid challenge may help distinguish SIADH from CSW [146]D.
NT-proBNP and Urodilatin
- NT-proBNP: Elevated levels are more commonly associated with CSW or renal salt wasting (RSW) due to volume expansion-induced cardiac stretch, helping to differentiate these from the euvolemic state of SIADH [50].
- Urodilatin: This natriuretic peptide is being investigated as a potential marker to identify RSW, which often mimics SIADH laboratory findings [66]D.
Etiology-Specific Workup
Once SIADH is confirmed, the underlying cause must be identified through targeted investigations:
- Medication Review: Evaluate for recent initiation of SSRIs (e.g., Escitalopram), SNRIs (e.g., Duloxetine), anticonvulsants, or chemotherapy agents (e.g., Osimertinib, Thiotepa) [53]D[139]C[140]C[151]D.
- Imaging: Chest CT to screen for (SCLC) and Brain MRI to evaluate for CNS tumors, infections (e.g., VZV meningoencephalitis), or postoperative changes following sellar region surgery [52]C[69]C[144]C[150]D.
- Infection Screening: Urine and blood cultures to rule out pathogens like Klebsiella pneumoniae or viral triggers [69]C[141]C.
- Endocrine Testing: Serum cortisol and TSH levels are mandatory to exclude secondary causes of hyponatremia [52]C.
| Parameter | SIADH | Cerebral Salt Wasting (CSW) |
|---|---|---|
| Volume Status | Euvolemic | Hypovolemic |
| Serum Sodium | <135 mmol/L | <135 mmol/L |
| Urine Sodium | Elevated (>40 mmol/L) | Markedly Elevated (>40 mmol/L) |
| Urine Output | Normal or Low | High (Polyuria) |
| Serum Uric Acid | Low (<4 mg/dL) | Low |
| FEurate | >12% (Normalizes after Na+ correction) | >12% (Remains high after Na+ correction) |
| NT-proBNP | Usually Normal | Often Elevated |
| Test | Typical SIADH Finding | Normal Range |
|---|---|---|
| Serum Sodium | <135 mmol/L | 135–145 mmol/L |
| Serum Osmolality | <275 mOsm/kg | 275–295 mOsm/kg |
| Urine Osmolality | >100 mOsm/kg | 50–1200 mOsm/kg |
| Urine Sodium | >40 mmol/L | Varies with intake |
| Serum Uric Acid | <4 mg/dL | 3.5–7.2 mg/dL |
| Serum Cortisol | Normal | 5–23 µg/dL (morning) |
| TSH | Normal | 0.4–4.0 mIU/L |
Differential Diagnosis
- ▸SIADH is a diagnosis of exclusion that requires the confirmation of hypotonicity, euvolemia, and the absence of renal, thyroid, or adrenal dysfunction.
- ▸The critical distinction between SIADH and Cerebral Salt Wasting (CSW) relies on volume status and the persistence of elevated fractional excretion of urate after sodium correction.
- ▸Drug-induced SIADH is common, particularly with SSRIs, SNRIs like Duloxetine 30 mg/day, and certain anticonvulsants.
The diagnosis of the syndrome of inappropriate antidiuresis (SIAD) is a process of exclusion. Clinicians must systematically differentiate it from other forms of hypotonic hyponatremia, which are categorized by volume status and underlying pathophysiology [54]D, [126]D. Accurate differentiation is critical, as misdiagnosis can lead to inappropriate fluid management and significant morbidity [50], [138]D.
Volume Status Assessment
The primary step in the differential diagnosis is the clinical assessment of extracellular fluid (ECF) volume [138]D. SIADH is characterized by euvolemia, though patients may have a slight subclinical increase in total body water without edema [52]C, [54]D.
- Hypovolemic Hyponatremia: Characterized by signs of dehydration (e.g., dry mucous membranes, decreased skin turgor, orthostatic hypotension). Causes include gastrointestinal losses, diuretic use, and Cerebral Salt Wasting (CSW) [50], [153]D.
- Hypervolemic Hyponatremia: Characterized by ECF expansion and edema. Primary causes include congestive heart failure, hepatic cirrhosis, and nephrotic syndrome [126]D, [153]D.
- Euvolemic Hyponatremia Mimics: Must exclude secondary adrenal insufficiency (hypocortisolism) and hypothyroidism, as these can present identically to SIADH with low plasma osmolality and high urine osmolality [52]C, [54]D, [157]D.
SIADH vs. Cerebral Salt Wasting (CSW)
Distinguishing SIADH from CSW is particularly challenging in neurosurgical and traumatic brain injury (TBI) patients [50], [55]C. While both present with hyponatremia and high urinary sodium (UNa >30 mmol/L), their management is diametrically opposed [50].
| Diagnostic Marker | SIADH | Cerebral Salt Wasting (CSW) |
|---|---|---|
| Volume Status | Euvolemic | Hypovolemic |
| Fractional Excretion of Urate (FEurate) | Elevated (>10-12%) during hyponatremia; normalizes after Na correction | Persistently elevated (>10-12%) after Na correction |
| Fractional Excretion of Phosphate | Typically normal | Elevated in some cases |
| NT-proBNP | Lower or normal | Often elevated due to natriuretic peptide release |
| Urine Output | Normal or decreased | Significantly increased (polyuria) |
| Primary Pathology | Inappropriate ADH secretion | Excessive renal sodium excretion |
Endocrine and Metabolic Mimics
- Secondary Adrenal Insufficiency: A deficiency in cortisol leads to increased ADH release. This must be ruled out via a morning cortisol or ACTH stimulation test [52]C, [157]D.
- Hypothyroidism: Severe hypothyroidism can reduce cardiac output and glomerular filtration rate, triggering non-osmotic ADH release [52]C.
- Reset Osmostat: A variant where ADH is secreted normally but the threshold for secretion is set at a lower plasma osmolality. These patients maintain a stable but low serum sodium level [153]D.
- Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD): A rare genetic condition caused by activating mutations in the V2 receptor (e.g., GNAS variants), leading to water reabsorption despite undetectable ADH levels [54]D, [67]D.
Drug-Induced Hyponatremia
Numerous medications can mimic or cause SIADH by stimulating ADH release or increasing renal sensitivity to ADH [53]D, [54]D.
| Drug Class | Specific Examples and Doses (where noted) |
|---|---|
| Antidepressants | Fluoxetine, Paroxetine, Sertraline, Citalopram, Escitalopram, Venlafaxine, Duloxetine (e.g., 30 mg/day), Bupropion [32]D, [56]C |
| Antipsychotics | Olanzapine [60]C |
| Anticonvulsants | Carbamazepine, Oxcarbazepine [53]D |
| Chemotherapy | Cyclophosphamide, Vincristine, Platinum-based agents [54]D |
| Other | Proton pump inhibitors (e.g., Omeprazole), NSAIDs, MDMA (Ecstasy) [32]D, [53]D |
Clinical Contexts and Rare Differentials
- Malignancy: Small cell lung cancer (SCLC) is the most common paraneoplastic cause [52]C, [130]C.
- Neurological Disorders: TBI [60]C, [62]C, pituitary surgery (incidence of post-op hyponatremia is significant) [18], Wernicke Encephalopathy [61]C, Normal Pressure Hydrocephalus [59]C, and Guillain-Barre Syndrome [155]D.
- Infections: COVID-19 (often IL-6 mediated) [157]D, Herpes Zoster (V1 distribution) [156]C, and pulmonary infections (pneumonia, tuberculosis) [54]D.
- Metabolic: Hereditary Tyrosinemia Type 1 (porphyria-like crisis) [65]C.
Pseudohyponatremia
Before diagnosing SIADH, clinicians must exclude pseudohyponatremia, where serum sodium appears low due to high concentrations of lipids or proteins in the blood, or hyperglycemia (translocational hyponatremia) [126]D. In these cases, measured plasma osmolality is typically normal or high, whereas in SIADH, it is always low (<275 mOsm/kg) [56]C, [126]D.
| Volume Status | Urine Sodium (UNa) | Common Etiologies |
|---|---|---|
| Hypovolemic | <20 mmol/L | Vomiting, diarrhea, third-spacing |
| Hypovolemic | >20 mmol/L | Diuretics, Cerebral Salt Wasting, Mineralocorticoid deficiency |
| Euvolemic | >30 mmol/L | SIADH, Hypothyroidism, Secondary Adrenal Insufficiency, Reset Osmostat |
| Hypervolemic | <20 mmol/L | Heart failure, Cirrhosis, Nephrotic syndrome |
| Hypervolemic | >20 mmol/L | Acute or chronic kidney injury |
Management: Acute and Emergency
- ▸Acute symptomatic hyponatremia requires 100-150 mL boluses of 3% hypertonic saline to rapidly reduce cerebral edema.
- ▸The maximum safe correction rate is 5-10 mEq/L in the first 24 hours to prevent osmotic demyelination syndrome.
- ▸Fluid restriction is the first-line treatment for asymptomatic SIADH, but tolvaptan 7.5 mg is more effective for rapid normalization.
The management of in the syndrome of inappropriate antidiuresis (SIADH) is dictated by the severity of neurological symptoms, the duration of the electrolyte imbalance, and the underlying etiology [101]D, [170]D. The primary goal in acute settings is to raise the plasma sodium (pNa) sufficiently to alleviate cerebral edema while avoiding osmotic demyelination syndrome (ODS) [173]D, [174]D.
Emergency Management of Symptomatic Hyponatremia
For patients presenting with severe symptoms (e.g., seizures, coma, or respiratory distress) or moderate symptoms (e.g., confusion, nausea, or headache), rapid correction is required [154]D, [174]D.
- Hypertonic Saline (3% NaCl): The preferred treatment is a 100-150 mL bolus of 3% hypertonic saline administered intravenously over 10–20 minutes [154]D, [174]D. This may be repeated up to three times or until symptoms improve [154]D.
- Correction Targets: The therapeutic target is an increase in pNa of 5–10 mEq/L within the first 24 hours [174]D. Clinicians must ensure the increase does not exceed 8 mEq/L in any subsequent 24-hour period to minimize ODS risk [174]D.
- Monitoring: Frequent biochemical monitoring is essential, often every 2–4 hours during the acute phase [154]D.
- Overcorrection Management: If the pNa correction exceeds targets, intervention with Dextrose 5% in water (D5W) or desmopressin may be required to slow or reverse the rise [125].
Management of Asymptomatic or Mild SIADH
In patients without severe neurological symptoms, more conservative measures are utilized to achieve gradual correction [154]D, [159].
- Fluid Restriction (FR): This remains the first-line therapy for most patients [159], [160]. Initial restriction is typically set at <1000 mL/day, though severe cases may require 500 mL/day [154]D, [125]. Approximately 50% of patients fail to respond to FR alone [154]D.
- Pharmacotherapy:
- Tolvaptan: An oral vasopressin V2-receptor antagonist. The starting dose is 7.5 mg daily, which can be titrated up to 60 mg daily based on response [125], [162]. It is more effective than FR for normalizing sodium levels but carries a higher risk of overcorrection [125], [63].
- Empagliflozin: This SGLT2 inhibitor (e.g., 10 mg or 25 mg daily) promotes osmotic diuresis via glucosuria and has shown efficacy in increasing pNa in SIADH [161], [158].
- Loop Diuretics: Furosemide 20–40 mg daily may be used in combination with oral sodium chloride to increase free water excretion [160].
- Oral Sodium Chloride: Supplementation with salt tablets (e.g., 1–3 g TID) is often used as an adjunct to FR [160].
Etiology-Specific Interventions
Management may require addressing the specific trigger of SIADH to achieve resolution [59]C, [168]C.
| Etiology | Specific Management Strategy |
|---|---|
| Normal Pressure Hydrocephalus (NPH) | Lumbar puncture to improve mental status and pNa [59]C. |
| HHV-6 Infection | Antiviral therapy with Foscarnet or Ganciclovir [168]C. |
| Post-Transsphenoidal Surgery | Early fluid restriction and potentially low-dose Tolvaptan 7.5 mg [173]D, [22]. |
| Drug-Induced | Immediate cessation of offending agents (e.g., SSRIs, certain antihypertensives) [164], [166]. |
| Neuromyelitis Optica (NMOSD) | Treatment of the underlying flare (e.g., corticosteroids) [102]C. |
Risks and Complications
- Osmotic Demyelination Syndrome (ODS): A devastating neurological condition caused by rapid shifts in osmolality. Risk factors include baseline pNa <105 mmol/L, malnutrition, and liver disease [173]D.
- Desalination: Administration of 0.9% Normal Saline (NS) can paradoxically worsen hyponatremia in SIADH if the urine osmolality is significantly higher than the saline osmolality [169]D. In such cases, the salt is excreted while the water is retained [169]D.
| Medication | Dosage | Mechanism | Evidence Level |
|---|---|---|---|
| Hypertonic Saline (3%) | 100-150 mL IV bolus | Rapidly increases serum osmolality | 5 [154]D, [174]D |
| Tolvaptan | 7.5 mg to 60 mg PO daily | V2-receptor antagonism | 1b [125], [162] |
| Empagliflozin | 10 mg to 25 mg PO daily | Osmotic diuresis via glucosuria | 1b [161] |
| Furosemide | 20-40 mg PO/IV daily | Increases free water clearance | 1b [160] |
| Sodium Chloride | 1-3 g PO TID | Increases solute load | 1b [160] |
Management: Chronic and Long-term
- ▸Fluid restriction is the first-line treatment but fails in approximately 50% of chronic SIADH cases.
- ▸Low-dose tolvaptan (3.75–7.5 mg) is an effective alternative to the standard 15 mg dose, reducing the risk of rapid sodium overcorrection.
- ▸Oral urea (30 g/day) or high-protein diets (90 g/day) provide effective osmotic diuresis for long-term sodium maintenance.
Chronic management of the (SIADH) focuses on maintaining serum sodium levels to prevent neurological complications while addressing the underlying etiology [54]D[136]. The primary goal is to achieve a stable serum sodium concentration, typically >130 mmol/L, through a combination of fluid management, solute supplementation, and pharmacological intervention [125][154]D.
Fluid Restriction
Fluid restriction (FR) remains the traditional first-line therapy for asymptomatic or mildly symptomatic chronic SIADH [154]D.
- Initial Target: An initial restriction of 500 mL/day is often required to achieve a positive sodium balance, though many protocols start at <1000 mL/day [125][154]D.
- Efficacy: FR is frequently unsuccessful; approximately 50% of patients fail to respond adequately to FR as a monotherapy [125][154]D.
- Limitations: Compliance is often poor due to persistent thirst, and FR may be impractical in patients requiring high fluid intake for nutrition or medications [127]D[129]C.
Pharmacological Interventions
When fluid restriction is insufficient or poorly tolerated, pharmacological agents are indicated to promote electrolyte-free water excretion [23][136].
Vasopressin Receptor Antagonists (Vaptans)
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, is highly effective in increasing serum sodium by blocking water reabsorption in the collecting ducts [125][48].
- Standard Dosing: The licensed starting dose is 15 mg daily, though recent evidence supports lower starting doses to minimize overcorrection risks [48][51].
- Low-Dose Protocols: Initial doses of 3.75 mg or 7.5 mg daily have demonstrated efficacy in correcting hyponatremia while reducing the incidence of rapid sodium shifts [51][177].
- Refractory Dosing: In challenging cases, such as those associated with , a twice-daily dosing regimen (e.g., 7.5 mg BID) may be utilized to maintain stable sodium levels [178]C.
- Monitoring: Frequent monitoring is required during initiation to ensure correction does not exceed 10–12 mmol/L in 24 hours to avoid [51][125].
Urea and Solute Supplementation
Increasing the solute load promotes osmotic diuresis, thereby increasing water excretion [73][124].
- Oral Urea: Effective for long-term management at doses of 30 g daily or 0.25–0.5 g/kg in pediatric populations [127]D[176]. While effective, its use is often limited by poor palatability [176].
- Protein Supplementation: High-protein intake (90 g daily) can serve as a precursor for endogenous urea production, effectively raising serum sodium through urea-induced osmotic diuresis [176].
- Salt Tablets: Oral sodium chloride supplementation is frequently used in conjunction with loop diuretics to maintain sodium balance, particularly in paraneoplastic SIADH [52]C[130]C.
Emerging and Alternative Therapies
- SGLT2 Inhibitors: Agents like Empagliflozin are emerging as novel treatments. They promote osmotic diuresis via glucosuria, increasing electrolyte-free water clearance [137]D.
- Loop Diuretics: Often used to decrease urinary concentrating ability, though they require concurrent salt intake to be effective [136].
- Demeclocycline: Historically used to induce a form of nephrogenic , though its use has declined due to potential nephrotoxicity and the availability of vaptans [137]D.
Etiology-Specific Management
Long-term resolution of SIADH requires treating the underlying cause [54]D.
- Malignancy: In patients with (SCLC) or , chemotherapy and radiation can lead to remission of SIADH [33]D[130]C. Recurrence of hyponatremia often serves as a marker for tumor relapse [130]C.
- Infection: Refractory SIADH associated with drug-resistant pathogens, such as Klebsiella pneumoniae, may resolve only after appropriate antimicrobial therapy [141]C.
- Medication Review: Discontinuation of offending agents (e.g., hydrochlorothiazide, olanzapine) is essential [60]C[141]C.
| Therapy | Mechanism | Typical Dose | Clinical Considerations |
|---|---|---|---|
| Fluid Restriction | Negative water balance | <800–1000 mL/day | First-line; high failure rate; poor compliance [125][154]D |
| Tolvaptan | V2-receptor antagonism | 3.75–15 mg daily | Highly effective; risk of overcorrection; requires monitoring [48][177] |
| Oral Urea | Osmotic diuresis | 30 g daily | Safe and effective; limited by poor palatability [124][176] |
| Protein Powder | Endogenous urea production | 90 g daily | Better tolerated than urea; promotes osmotic diuresis [176] |
| Salt Tablets | Solute loading | Variable | Often combined with loop diuretics [52]C[130]C |
Complications and Prognosis
- ▸Chronic SIADH is a major risk factor for falls, osteoporosis, and bone fractures due to subclinical neurological and metabolic impairment.
- ▸Osmotic Demyelination Syndrome (ODS) is a preventable but devastating complication of rapid sodium correction, with a risk threshold of >10-12 mmol/L per 24 hours.
- ▸In oncological and infectious contexts, such as SCLC and TBM, the presence and recurrence of hyponatremia are independent markers of poor prognosis and disease relapse.
The prognosis of SIADH is intrinsically linked to the severity of hyponatremia, the speed of its development, and the nature of the underlying etiology [138]D[182]D[185]D. While often viewed through the lens of acute neurological emergencies, SIADH is associated with significant chronic morbidity and increased mortality across various clinical settings [73][185]D.
Acute Neurological Complications
Acute hyponatremia (developing in <48 hours) poses an immediate risk of cerebral edema as water moves into the relatively hypertonic intracellular space of the brain [182]D. If the compensatory extrusion of organic osmolytes is overwhelmed, severe complications occur:
- Generalized tonic-clonic seizures [65]C
- Progressive neurological deterioration and coma [65]C
- Increased intracranial pressure [73]
- Brainstem herniation [182]D
- Non-specific symptoms: Nausea, vomiting, and headache [65]C[184]D.
Chronic Morbidity
Chronic hyponatremia (lasting >48 hours) was historically considered "asymptomatic" due to brain volume regulation. However, evidence demonstrates that chronic low sodium levels lead to multisystem impairment [185]D.
| System | Complications and Manifestations |
|---|---|
| Neurological | Attention deficits, dizziness, gait disturbances, and increased frequency of falls [185]D. |
| Musculoskeletal | Sarcopenia, accelerated osteoporosis, and increased risk of bone fractures [185]D. |
| Metabolic | Hypercalciuria and an increased risk of nephrolithiasis (kidney stones) [185]D. |
| Cellular | In vitro studies suggest increased cell proliferation and motility in low-sodium environments [185]D. |
Treatment-Related Complications: Osmotic Demyelination Syndrome (ODS)
(ODS), formerly known as central pontine myelinolysis, is the most severe complication of SIADH management [48][138]D[182]D. It occurs when chronic hyponatremia is corrected too rapidly, leading to osmotic stress that destroys the myelin sheath [182]D[183]D.
- Risk Thresholds: To prevent ODS, correction should generally not exceed 10–12 mmol/L in 24 hours or 18 mmol/L in 48 hours [182]D.
- Pharmacological Risks:
- Tolvaptan: In patients receiving Tolvaptan 7.5 mg, the rate of overcorrection (increase ≥10 mmol/L in 24 hours) was reported at 8.7% [51]. Higher doses (e.g., Tolvaptan 15 mg) or dose escalation (up to 60 mg/day) require intensive monitoring to avoid exceeding safety limits [48][162].
- Urea: Systematic reviews of oral urea (doses ranging from 7.5 g to 90 g daily) show a very low incidence of ODS, suggesting it may be a safer alternative for some patients [73][124].
- SGLT2 Inhibitors: Empagliflozin 25 mg QD has been studied for SIADH; while it increases sodium, the risk of ODS appears low in initial trials [161].
Prognostic Indicators by Etiology
The underlying cause of SIADH is a primary determinant of long-term survival and recurrence [185]D.
- Malignancy: In (SCLC), the recurrence of hyponatremia often serves as a surrogate marker for tumor relapse [130]C. Ectopic olfactory neuroblastoma (eONB) associated with SIADH is linked to poorer disease control compared to orthotopic tumors [19].
- Infectious Disease: In (TBM), hyponatremia is an independent predictor of poor outcomes. Mortality in TBM patients with hyponatremia was 3.9%, whereas those with normal sodium levels had 0% mortality in one cohort [186]D.
- COVID-19: Hyponatremia in the setting of SARS-CoV-2 infection is associated with higher mortality and increased severity of illness [109]D[110]D.
- Post-Surgical: Following transsphenoidal surgery for pituitary adenomas, SIADH is a common postoperative complication [184]D. While 53.1% of patients see improvement after tumor resection, others may develop permanent diabetes insipidus or require long-term sodium management [163][184]D.
Hospital and Quality of Life Outcomes
SIADH significantly increases the burden on the healthcare system. It is associated with a prolonged length of stay (LOS) in both general wards and intensive care units [48][73][163]. Effective correction of sodium levels, particularly with vaptans or urea, has been shown to improve quality-of-life scores and reduce hospital resource utilization compared to fluid restriction alone [48][63][125].
| Factor | Impact on Prognosis |
|---|---|
| Etiology | Malignancy-associated SIADH (e.g., SCLC) has a higher recurrence rate and poorer survival [130]C[185]D. |
| Sodium Level | Lower baseline sodium is associated with higher mortality in TBM and COVID-19 [110]D[186]D. |
| Correction Rate | Rapid correction (>12 mmol/L/day) increases the risk of permanent neurological damage (ODS) [182]D. |
| Treatment Response | Failure to respond to fluid restriction often necessitates pharmacological intervention to reduce LOS [63][125]. |
Special Populations
- ▸Geriatric patients experience a baseline decline in serum sodium of 0.14 mmol/L per year of age, increasing vulnerability to medication-induced SIADH.
- ▸Post-operative SIADH is a major complication of transsphenoidal pituitary surgery, requiring careful differentiation from Cerebral Salt Wasting Syndrome using BNP and IVC diameter.
- ▸Severe acute hyponatremia (<120 mmol/L) in SIADH can precipitate Takotsubo cardiomyopathy, a reversible stress-induced heart failure.
The management and clinical presentation of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) vary significantly across specific patient demographics. Vulnerable groups, including geriatric patients, post-operative neurosurgical cases, and endurance athletes, require tailored diagnostic and therapeutic approaches due to unique physiological triggers and risks. [63], [68]D, [83]D
Geriatric Patients
Hyponatremia is the most common electrolyte disorder in the elderly, with serum sodium levels decreasing by 0.14 mmol/L for every one-year increase in age. [68]D Older adults often present with a high burden of comorbid illness and are frequently prescribed hyponatremia-inducing medications (HIMs). [84]D, [192]D Chronic SIADH in this population is associated with increased bone fragility and fracture risk. [158] Hyponatremia stimulates osteoclast activation and impairs osteoblast function, as evidenced by alterations in biochemical markers such as C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (PINP). [158]
Medication-Induced SIADH in the Elderly
Polypharmacy significantly elevates the risk of severe hyponatremia. [84]D Common culprits include:
- SSRIs/SNRIs: Fluoxetine, paroxetine, sertraline, citalopram, escitalopram, and venlafaxine. [32]D
- Duloxetine: Doses as low as 20 mg/day or 30 mg/day have been linked to asymptomatic or symptomatic SIADH within 24 hours to 40 days of initiation. [56]C, [116]C
- Vortioxetine: Recently identified as a potential cause of SIADH in patients with major depressive disorder. [190]C
- Bupropion: A norepinephrine-dopamine reuptake inhibitor (NRI) associated with SIADH risk. [32]D
Post-operative and Neurosurgical Patients
SIADH is a frequent complication following intracranial procedures, particularly those involving the hypothalamic-pituitary axis. [70]D, [189]D
Transsphenoidal Surgery (TSS)
In patients undergoing TSS for resection, SIADH and central are common. [70]D These complications often result from the intraoperative manipulation of the posterior pituitary gland (PPG). [70]D While the endoscopic approach (EA) has surpassed the microscopic approach (MA) in frequency, both carry risks of postoperative sodium fluctuations. [49], [134]D
Differentiating SIADH from Cerebral Salt Wasting Syndrome (CSWS)
Following hypothalamic tumor surgery, clinicians must distinguish SIADH from (CSWS) to avoid inappropriate fluid management. [189]D Key parameters for differentiation include:
- Plasma Brain Natriuretic Peptide (BNP): Elevated in CSWS. [189]D
- 24-hour Urine Sodium and Volume: Typically higher in CSWS. [189]D
- Inferior Vena Cava Diameter (IVCD): Reduced in CSWS (hypovolemia) but normal or slightly increased in SIADH (euvolemia). [189]D
Exercise-Associated Hyponatremia (EAH)
In long-distance runners and marathon participants, SIADH-like presentations may be linked to fructose metabolism. [83]D Fructose ingestion or endogenous production via the polyol pathway can stimulate vasopressin secretion, contributing to exercise-associated hyponatremia. [83]D
Malignancy-Specific Considerations
Paraneoplastic SIADH is most classically associated with (SCLC), where it may serve as an early marker of relapse or disease progression. [52]C, [130]C Other rare oncological associations include:
- Neuroblastoma: Ectopic olfactory neuroblastoma (eONB), thymic neuroblastoma, and anterior mediastinal neuroblastoma in adults. [19], [42]C, [58]C
- Neuroendocrine Prostate Cancer (NEPC): A rare subtype of prostate cancer that may manifest initially as SIADH. [187]
- Osimertinib Therapy: Used in EGFR-mutated , this tyrosine kinase inhibitor has been reported to induce SIADH approximately two months into treatment. [26]C
Other Clinical Subgroups
- COVID-19 Patients: Euvolemic hyponatremia is the most frequent sodium disorder in hospitalized COVID-19 patients and is associated with increased mortality. [191]D SIADH has also been reported as a rare complication following COVID-19 vaccination. [165]C
- Anti-LGI1 Encephalitis: Between 60% and 88% of patients with this autoimmune encephalitis develop hyponatremia, often attributed to SIADH. [181]D
- Multiple System Atrophy (MSA): Hypothalamic involvement in MSA can impair thermoregulation and predispose patients to SIADH, especially when triggered by medications like duloxetine. [56]C
- Normal Pressure Hydrocephalus (NPH): SIADH is a less common association; however, lumbar puncture has been shown to rapidly improve both confusion and hyponatremia in these cases. [59]C
| Parameter | SIADH | CSWS |
|---|---|---|
| Volemic Status | Euvolemic | Hypovolemic |
| BNP Levels | Normal/Low | Elevated |
| IVC Diameter | Normal/Increased | Decreased |
| Urine Volume | Decreased/Normal | Significantly Increased |
| Primary Treatment | Fluid Restriction | Fluid/Sodium Replacement |
| Drug Class | Specific Agents | Clinical Context |
|---|---|---|
| SNRIs | Duloxetine (20-30 mg), Venlafaxine | Pain, Depression in elderly [56]C, [116]C |
| SSRIs | Fluoxetine, Escitalopram, Sertraline | Most common HIMs in geriatric care [32]D |
| Antidepressants | Vortioxetine, Bupropion | Emerging causes of SIADH [32]D, [190]C |
| TKIs | Osimertinib | EGFR-mutated lung adenocarcinoma [26]C |
| Other | Duloxetine | Multiple System Atrophy (MSA) triggers [56]C |
Guidelines and Resources
- ▸The European guidelines provide a standardized classification of hyponatremia based on biochemical severity (mild, moderate, profound) and symptom profile.
- ▸Diagnosis of SIADH requires meeting specific essential criteria, including hypotonicity, clinical euvolemia, and elevated urine sodium (>30 mmol/L).
- ▸Specialized guidelines exist for unique clinical contexts, including exercise-associated hyponatremia and post-pituitary surgery management.
The clinical management of SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion) is guided by several international and regional consensus statements. These documents provide standardized definitions, diagnostic algorithms, and therapeutic hierarchies for in various clinical settings [193][196][198].
European Clinical Practice Guidelines (2014)
A joint task force from the European Society of Intensive Care Medicine (ESICM), the European Society of Endocrinology (ESE), and the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) published the most comprehensive guidelines for hyponatremia to date [193][194]. These guidelines define hyponatremia as a serum sodium concentration <135 mmol/L [193].
Classification and Severity
The European guidelines categorize hyponatremia based on three primary factors: biochemical severity, time of development, and clinical symptoms [194].
- Biochemical Severity:
- Mild: 130–134 mmol/L [194].
- Moderate: 125–129 mmol/L [194].
- Profound: <125 mmol/L [194].
- Time of Development:
- Acute: Duration <48 hours [193].
- Chronic: Duration ≥48 hours or unknown duration [193].
- Clinical Symptoms:
- Moderately severe: Nausea without vomiting, confusion, headache [193].
- Severe: Vomiting, cardiorespiratory distress, abnormal somnolence, seizures, coma (Glasgow Coma Scale ≤8) [193].
Diagnostic Criteria for SIADH
The European guidelines establish specific essential and supplemental criteria for the diagnosis of SIADH [193][194]:
Essential Criteria:
- Hypotonic hyponatremia (measured serum osmolality <275 mOsm/kg) [193].
- Urine osmolality >100 mOsm/kg during hypotonicity [194].
- Clinical euvolemia (absence of signs of extracellular fluid volume depletion or expansion) [193].
- Urine sodium concentration >30 mmol/L with normal dietary salt and water intake [193].
- Absence of adrenal, thyroid, pituitary, or renal insufficiency [193].
- No recent use of diuretic agents [194].
Supplemental Criteria:
- Serum uric acid <4 mg/dL [193].
- Blood urea nitrogen <10 mg/dL [193].
- Failure to correct hyponatremia after 0.9% saline infusion [193].
- Fractional sodium excretion >1% [193].
- Fractional urea excretion >55% [193].
Spanish Consensus Algorithms (2013-2014)
A multidisciplinary group of Spanish medical societies developed two specific algorithms for SIADH management in hospitalized patients, focusing on the distinction between acute/symptomatic and chronic/asymptomatic presentations [196]. These guidelines emphasize the role of the hospital pharmacist in the multidisciplinary team to ensure safe preparation of hypertonic solutions [196].
Post-Pituitary Surgery Guidelines
The Spanish Society of Endocrinology and Nutrition (SEEN) provides specific guidelines for managing SIADH following pituitary surgery [198]. They highlight that SIADH often occurs as the second phase of a "triple response" (diabetes insipidus, followed by SIADH, followed by permanent diabetes insipidus) and requires daily weight monitoring and strict intake/output logs [198].
Wilderness Medical Society (WMS) Guidelines
The WMS provides practice guidelines for Exercise-Associated Hyponatremia (EAH), defined as a serum sodium <135 mmol/L occurring during or up to 24 hours after prolonged physical activity [195][197]. These guidelines are designed for austere environments where medical evacuation may be delayed [197].
Guideline-Recommended Pharmacological Options
While management strategies vary by severity, the following pharmacological options and doses are cited within the major guidelines:
- Hypertonic Saline (3% NaCl): 150 mL bolus over 20 minutes, repeatable until a 5 mmol/L increase in serum sodium is achieved in severe cases [193].
- Urea: 0.25–0.50 g/kg per day for chronic moderate-to-profound hyponatremia [193].
- Tolvaptan: 15 mg QD as a starting dose for chronic SIADH where fluid restriction is ineffective or not tolerated [196].
- Fluid Restriction: Generally recommended as the first-line non-pharmacological intervention for non-emergency SIADH [193][196].
| Guideline Source | Focus Area | Key Definition/Threshold |
|---|---|---|
| European Society of Endocrinology (ESE) [193][194] | General Hyponatremia | Serum Na <135 mmol/L; Profound <125 mmol/L |
| Spanish Consensus Group [196] | Hospitalized SIADH Patients | Multidisciplinary management algorithms |
| Wilderness Medical Society (WMS) [195][197] | Exercise-Associated Hyponatremia (EAH) | Serum Na <135 mmol/L within 24h of activity |
| Spanish Society of Endocrinology (SEEN) [198] | Post-Pituitary Surgery | Monitoring for SIADH vs. |
References
- [1]
Meulendijks D, Mannesse CK, Jansen PA et al.. “Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.” Drug safety (2010). PMID: 20082537 ↗
L2aSR_OBSCited in: Definition and Components - [2]
Castle-Kirszbaum M, Kyi M, Wright C et al.. “Hyponatraemia and hypernatraemia: Disorders of Water Balance in Neurosurgery.” Neurosurgical review (2021). PMID: 33389341 ↗
L5REVIEW_NARRATIVECited in: Definition and Components - [3]
Moriyama B, Henning SA, Leung J et al.. “Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.” Mycoses (2012). PMID: 22126626 ↗
L5REVIEW_NARRATIVECited in: Definition and Components - [4]
Elhassan EA, Schrier RW. “Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists.” Current opinion in nephrology and hypertension (2011). PMID: 21252664 ↗
L5REVIEW_NARRATIVECited in: Definition and Components - [5]
Praharaj DL, Anand AC. “Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.” Journal of clinical and experimental hepatology (2022). PMID: 35535075 ↗
L5REVIEW_NARRATIVECited in: Definition and Components - [6]
Gibbons J, Dreimane D. “The Utility of Copeptin Measurement in Hospitalized Pediatric Patients with Syndrome of Inappropriate Antidiuretic Secretion.” Hormone research in paediatrics (2025). PMID: 40544834 ↗
L5OTHERCited in: Definition and Components, Etiology, Workup and Laboratory Findings - [7]
Kann PH. “[Pituitary coma].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2012). PMID: 22911165 ↗
L5REVIEW_NARRATIVECited in: Definition and Components - [8]
Estephan K, Charbonneau L, Chennou F et al.. “The surgical management of Cushing disease: a case series from a Canadian tertiary center.” Neurological research (2025). PMID: 41433699 ↗
L4CASE_REPORTCited in: Definition and Components - [9]
Anandan C, Khuder SA, Koffman BM. “Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barré syndrome.” Muscle & nerve (2017). PMID: 28039863 ↗
L5OTHERCited in: Definition and Components - [10]
Asemota AO, Ishii M, Brem H et al.. “Comparison of Complications, Trends, and Costs in Endoscopic vs Microscopic Pituitary Surgery: Analysis From a US Health Claims Database.” Neurosurgery (2017). PMID: 28859453 ↗
L5OTHERCited in: Definition and Components - [11]
Murthy SB, Caplan J, Levy AP et al.. “Haptoglobin 2-2 Genotype Is Associated With Cerebral Salt Wasting Syndrome in Aneurysmal Subarachnoid Hemorrhage.” Neurosurgery (2016). PMID: 26348010 ↗
L5OTHERCited in: Definition and Components - [12]
Fenske WK, Christ-Crain M, Hörning A et al.. “A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis.” Journal of the American Society of Nephrology : JASN (2014). PMID: 24722436 ↗
L5OTHERCited in: Definition and Components - [13]
Giuliani C, Cangioli M, Beck-Peccoz P et al.. “Awareness and management of hyponatraemia: the Italian Hyponatraemia Survey.” Journal of endocrinological investigation (2013). PMID: 23558469 ↗
L5OTHERCited in: Definition and Components - [14]
Metsis V, Huang H, Andronesi OC et al.. “Heterogeneous data fusion for brain tumor classification.” Oncology reports (2012). PMID: 22842996 ↗
L5OTHERCited in: Definition and Components - [15]
Fenske W, Störk S, Koschker AC et al.. “Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18477658 ↗
L5OTHERCited in: Definition and Components - [16]
Goyal-Honavar A, Konar S, Sadashiva N et al.. “Differences in clinical profiles of patients with symptomatic and asymptomatic apoplexy in pituitary neuroendocrine tumors.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40957381 ↗
L5OTHERCited in: Definition and Components - [17]
Wang M, Zhang L, Jia M et al.. “Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study.” BMC nephrology (2022). PMID: 35590283 ↗
L5OTHERCited in: Definition and Components - [18]
Webb KL, Reilly CE, Hinkle ML et al.. “Incidence and risk factors of hyponatremia after transsphenoidal surgery: a systematic meta-analysis.” Neurosurgical review (2025). PMID: 40892282 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology, Differential Diagnosis, Management: Chronic and Long-term - [19]
Daloiso A, Gaudioso P, Vinciguerra A et al.. “Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis.” International forum of allergy & rhinology (2025). PMID: 39661032 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology, Diagnostic Criteria, Complications and Prognosis, Special Populations - [20]
Martinez-Perez R, Kortz MW, Florez-Perdomo W et al.. “Endocrinological outcomes after transcranial resection of tuberculum sellae meningiomas: a systematic review and meta-analysis.” Neurosurgical review (2022). PMID: 35149901 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Diagnostic Criteria, Complications and Prognosis - [21]
Bartalis E, Gergics M, Tinusz B et al.. “Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.” Frontiers in medicine (2021). PMID: 34950676 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [22]
Perez-Vega C, Tripathi S, Domingo RA et al.. “Fluid Restriction After Transsphenoidal Surgery for the Prevention of Delayed Hyponatremia: A Systematic Review and Meta-Analysis.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2021). PMID: 34265453 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Management: Acute and Emergency - [23]
Krisanapan P, Tangpanithandee S, Thongprayoon C et al.. “Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2023). PMID: 37685548 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Management: Acute and Emergency, Management: Chronic and Long-term, Complications and Prognosis - [24]
Wardhana DPW, Soetomo CT, Satyarsa ABS et al.. “Critical shift phase in deep vein thrombosis development after major sellar region tumor surgeries: a systematic review.” Annals of medicine (2025). PMID: 41392925 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology, Workup and Laboratory Findings - [25]
Falhammar H, Skov J, Calissendorff J et al.. “Reduced risk for hospitalization due to hyponatraemia in lithium treated patients: A Swedish population-based case-control study.” Journal of psychopharmacology (Oxford, England) (2021). PMID: 32684112 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Management: Acute and Emergency - [26]
Skribek M, Bozoky B, Tsakonas G. “Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report.” Lung cancer (Amsterdam, Netherlands) (2022). PMID: 35276629 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors, Special Populations - [27]
Hossain MF, Kharel M, Husna AU et al.. “Prevalence of Electrolyte Imbalance in Patients With Acute Stroke: A Systematic Review.” Cureus (2023). PMID: 37692728 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [28]
Khidir RJY, Ibrahim BAY, Adam MHM et al.. “Prevalence and outcomes of hyponatremia among COVID-19 patients: A systematic review and meta-analysis.” International journal of health sciences (2022). PMID: 36101848 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [29]
Mohamed MFH, Ahmed AOE, Habib MB et al.. “The prevalence of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in brucellosis patients: Systematic review and meta-analysis.” Annals of medicine and surgery (2012) (2022). PMID: 35198172 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [30]
Moscona-Nissan A, López-Hernández JC, González-Morales AP. “Mirtazapine Risk of Hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone Secretion in Adult and Elderly Patients: A Systematic Review.” Cureus (2021). PMID: 35141079 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [31]
Anastassopoulou C, Panagiotopoulos AP, Ferous S et al.. “RSV vaccines and Guillain-Barré syndrome: Insights into an emerging concern.” Vaccine (2025). PMID: 40466480 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Management: Acute and Emergency - [32]
Mo H, Channa Y, Ferrara TM et al.. “Hyponatremia Associated with the Use of Common Antidepressants in the All of Us Research Program.” Clinical pharmacology and therapeutics (2025). PMID: 39540435 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology, Differential Diagnosis, Special Populations - [33]
Dang S, Zhang S, Zhao J et al.. “The syndrome of inappropriate antidiuretic hormone associated with nasal and paranasal malignant tumors.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2024). PMID: 38163817 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnostic Criteria, Management: Chronic and Long-term - [34]
Maesaka JK, Imbriano LJ, Grant C et al.. “High prevalence of renal salt wasting induced by haptoglobin-related protein without signal peptide is linked to new syndrome of salt wasting in Alzheimer disease.” Kidney research and clinical practice (2024). PMID: 37919890 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [35]
Akaishi T, Tarasawa K, Matsumoto Y et al.. “Associations between neuromyelitis optica spectrum disorder, Sjögren's syndrome, and conditions with electrolyte disturbances.” Journal of the neurological sciences (2023). PMID: 37515845 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [36]
Charalambous LT, Adil SM, Rajkumar S et al.. “A Nationwide Analysis of Aneurysmal Subarachnoid Hemorrhage Mortality, Complications, and Health Economics in the USA.” Translational stroke research (2023). PMID: 35881231 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features - [37]
Roser P, Mende KC, Dimitriadis GK et al.. “The Potential of Self-Assessment and Associated Factors for Delayed Symptomatic Hyponatremia Following Transsphenoidal Surgery: A Single Center Experience.” Journal of clinical medicine (2022). PMID: 36615106 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Maesaka JK, Imbriano LJ, Grant C et al.. “New Approach to Hyponatremia: High Prevalence of Cerebral/Renal Salt Wasting, Identification of Natriuretic Protein That Causes Salt Wasting.” Journal of clinical medicine (2022). PMID: 36556061 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [39]
Sumisławski P, Piffko A, Huckhagel T et al.. “Exoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a retrospective single-center study on 388 patients.” Neurosurgical review (2022). PMID: 36136255 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Complications and Prognosis - [40]
Léveillé E, Aljassar M, Beland B et al.. “Determinants of hyponatremia following a traumatic brain injury.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022). PMID: 35037099 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [41]
Chang MT, Jitaroon K, Song S et al.. “Venous thromboembolism rates and risk factors following endoscopic skull base surgery.” International forum of allergy & rhinology (2022). PMID: 34894093 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [42]
Kennedy GT, Sande CM, Surrey LF et al.. “Anterior Mediastinal Neuroblastoma Associated with Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Morphologic, Immunohistochemical, and Genetic Case Report and Review of the Literature.” International journal of surgical pathology (2022). PMID: 35188820 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors, Pathophysiology, Special Populations - [43]
Coupaye M, Pellikaan K, Goldstone AP et al.. “Hyponatremia in Children and Adults with Prader-Willi Syndrome: A Survey Involving Seven Countries.” Journal of clinical medicine (2021). PMID: 34441851 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [44]
Sorba EL, Staartjes VE, Voglis S et al.. “Diabetes insipidus and syndrome of inappropriate antidiuresis (SIADH) after pituitary surgery: incidence and risk factors.” Neurosurgical review (2021). PMID: 32583307 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Wu R, Li C, Wang Z et al.. “A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.” Translational lung cancer research (2020). PMID: 33489807 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [46]
Christ-Crain M, Hoorn EJ, Sherlock M et al.. “ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of diabetes insipidus and hyponatraemia.” European journal of endocrinology (2020). PMID: 32380474 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [47]
Maesaka JK, Imbriano LJ, Miyawaki N. “Evolution and evolving resolution of controversy over existence and prevalence of cerebral/renal salt wasting.” Current opinion in nephrology and hypertension (2020). PMID: 31904619 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [48]
Lewellyn D, Nuamek T, Ostarijas E et al.. “Low-Dose Tolvaptan for the Treatment of Syndrome of Inappropriate Antidiuretic Hormone-Associated Hyponatremia: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Clinical Effectiveness and Safety.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 40288608 ↗
L2aSR_OBSCited in: Etiology, Diagnostic Criteria, Workup and Laboratory Findings, Differential Diagnosis, Management: Chronic and Long-term, Complications and Prognosis - [49]
Eördögh M, Bárány L, Rosenstengel C et al.. “Comparison of endoscopic and endoscope-assisted microscopic transsphenoidal surgery for pituitary adenoma resection: a prospective randomized study.” Frontiers in endocrinology (2025). PMID: 40766292 ↗
L1bRCTCited in: Etiology, Diagnostic Criteria, Complications and Prognosis, Special Populations - [50]
Assadi F. “Diagnostic Utility of Fractional Excretion of Urate, Urinary Phosphate and Brain Natriuretic Peptide in Distinguishing Cerebral/Renal Salt Wasting From SIADH in Neurologically Ill Children: A Systematic Review.” Clinical endocrinology (2026). PMID: 41058069 ↗
L2aSR_OBSCited in: Etiology, Diagnostic Criteria, Workup and Laboratory Findings, Differential Diagnosis - [51]
Llewellyn DC, Oštarijaš E, Sahadevan S et al.. “Efficacy and Safety of Low-Dose Tolvaptan (7.5 mg) in the Treatment of Inpatient Hyponatremia: A Retrospective Study.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 39733944 ↗
L2bCOHORTCited in: Etiology, Diagnostic Criteria, Differential Diagnosis, Management: Chronic and Long-term, Complications and Prognosis, Special Populations - [52]
Bao S, Qin L, Zhang Y et al.. “Refractory hyponatremia in small cell lung cancer: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 41890180 ↗
L4CASE_REPORTCited in: Etiology, Workup and Laboratory Findings, Differential Diagnosis, Management: Chronic and Long-term, Special Populations - [53]
Mannheimer B, Lindh JD, Fahlén CB et al.. “Drug-induced hyponatremia in clinical care.” European journal of internal medicine (2025). PMID: 40328519 ↗
L5REVIEW_NARRATIVECited in: Etiology, Workup and Laboratory Findings, Differential Diagnosis - [54]
Rosner MH, Rondon-Berrios H, Sterns RH. “Syndrome of Inappropriate Antidiuresis.” Journal of the American Society of Nephrology : JASN (2025). PMID: 39621420 ↗
L5REVIEW_NARRATIVECited in: Etiology, Pathophysiology, Differential Diagnosis, Management: Chronic and Long-term - [55]
James V, Nimkoff L. “Multiphase management of sodium imbalance following traumatic brain injury: a case-based review.” BMC pediatrics (2025). PMID: 40730974 ↗
L4CASE_REPORTCited in: Etiology, Pathophysiology, Clinical Features, Workup and Laboratory Findings, Differential Diagnosis, Management: Acute and Emergency - [56]
Zhao W, Shi J, Sarma AK et al.. “Fever and syndrome of inappropriate antidiuretic hormone secretion in a patient with multiple system atrophy after treatment with duloxetine.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41656390 ↗
L4CASE_REPORTCited in: Etiology, Clinical Features, Workup and Laboratory Findings, Differential Diagnosis, Special Populations - [57]
Saraceno E, Serra I, Bracci B et al.. “SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights.” International journal of molecular sciences (2026). PMID: 41596311 ↗
L4CASE_REPORTCited in: Etiology, Diagnostic Criteria - [58]
Lérias S, Cabrera R, Branquinho-Ruivo L et al.. “Molecular characterization of a thymic neuroblastoma in an adult associated with inappropriate antidiuretic hormone secretion syndrome.” Virchows Archiv : an international journal of pathology (2026). PMID: 40167643 ↗
L4CASE_REPORTCited in: Etiology, Special Populations - [59]
McCoin N, Marcum S, Martin J. “Case report: Hyponatremia due to syndrome of inappropriate antidiuresis associated with normal pressure hydrocephalus.” The American journal of emergency medicine (2025). PMID: 40187989 ↗
L4CASE_REPORTCited in: Etiology, Diagnostic Criteria, Differential Diagnosis, Management: Acute and Emergency, Special Populations - [60]
Petria I, Indirli R, Mantovani B et al.. “Recurrent hyponatremia due to syndrome of inappropriate antidiuresis after traumatic brain injury: two case reports.” Frontiers in endocrinology (2025). PMID: 40115742 ↗
L4CASE_REPORTCited in: Etiology, Differential Diagnosis, Management: Chronic and Long-term - [61]
Braun C, Cohen C, Webb L. “Wernicke Encephalopathy Presenting With Syndrome of Inappropriate Antidiuretic Hormone.” Pediatric neurology (2025). PMID: 39793149 ↗
L4CASE_REPORTCited in: Etiology, Diagnostic Criteria, Differential Diagnosis - [62]
Liu Y, Tang J, Zhou M et al.. “Case report: Persistent syndrome of inappropriate antidiuresis after traumatic brain injury: spontaneous resolution and impact on RAAS and bone metabolism over five years.” Frontiers in endocrinology (2024). PMID: 39926394 ↗
L4CASE_REPORTCited in: Etiology, Differential Diagnosis - [63]
Martínez González Á, González Nunes M, Rodeiro Escobar P et al.. “[Tolvaptan versus fluid restriction in the treatment of hyponatremia due to inappropriate antidiuretic hormone secretion: efficacy and safety analysis in a cohort study].” Nutricion hospitalaria (2025). PMID: 39873469 ↗
L2bCOHORTCited in: Etiology, Diagnostic Criteria, Differential Diagnosis, Management: Acute and Emergency, Management: Chronic and Long-term, Complications and Prognosis, Special Populations - [64]
Bogusz-Wójcik A, Rakusiewicz-Krasnodębska K, Hautz W et al.. “Correlation Between Endocrine and Other Clinical Factors with Peripapillary Retinal Nerve Fiber Layer Thickness After Surgical Treatment of Pediatric Craniopharyngioma.” Biomedicines (2026). PMID: 41595773 ↗
L5OTHERCited in: Etiology - [65]
Basan H, Bilginer Gürbüz B, Gürbüz F et al.. “Management of porphyria-like syndrome in tyrosinemia type 1.” Journal of pediatric endocrinology & metabolism : JPEM (2026). PMID: 41711566 ↗
L4CASE_REPORTCited in: Etiology, Diagnostic Criteria, Workup and Laboratory Findings, Differential Diagnosis, Management: Chronic and Long-term, Complications and Prognosis - [66]
Della Corte V, Agnello L, Norrito R et al.. “Urinary urodilatin levels in patients with renal salt wasting syndrome as a possible new diagnostic marker. A pilot study.” Frontiers in pharmacology (2025). PMID: 40567378 ↗
L5OTHERCited in: Etiology, Workup and Laboratory Findings - [67]
Carcavilla A, Pereda A, Miyado M et al.. “Germline-derived GNAS-Gsα variants associated with both gain-of-function and loss-of-function phenotypes.” European journal of endocrinology (2025). PMID: 40172207 ↗
L5OTHERCited in: Etiology, Differential Diagnosis - [68]
Kawahara T, Toda M, Kanagawa M et al.. “Etiology and Clinical Features of Patients With Hyponatremia in the Emergency Department: A Cross-sectional Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40130271 ↗
L5OTHERCited in: Etiology, Diagnostic Criteria, Differential Diagnosis, Special Populations - [69]
Żak-Skryśkiewicz Z, Krupińska P, Bieńkowski C et al.. “Hyponatremia Due to VZV-Induced SIADH in an Older Patient: Case Report and Literature Review.” Infectious disease reports (2025). PMID: 40981326 ↗
L4CASE_REPORTCited in: Etiology, Workup and Laboratory Findings - [70]
Juncker RB, Finger G, Damante MA et al.. “Real-time intraoperative ultrasound imaging of the posterior pituitary gland during endoscopic endonasal approach.” Acta neurochirurgica (2024). PMID: 39546020 ↗
L5OTHERCited in: Etiology, Diagnostic Criteria, Special Populations - [71]
Zhou XH, Li Y, Wang CJ et al.. “[Syndrome of inappropriate antidiuretic hormone secretion after hematopoietic stem cell transplantation in a child: a case report and literature review].” Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics (2026). PMID: 41766157 ↗
L4CASE_REPORTCited in: Etiology, Workup and Laboratory Findings - [72]
Vera-Cáceres CH, García-Huguet M, Gil de Genover A et al.. “Dysautonomia after COVID-19 infection: A case report.” Neurologia (2026). PMID: 41579008 ↗
L4CASE_REPORTCited in: Etiology, Workup and Laboratory Findings - [73]
Wendt R, Fenves AZ, Geisler BP. “Use of Urea for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: A Systematic Review.” JAMA network open (2023). PMID: 37902751 ↗
L2aSR_OBSCited in: Pathophysiology, Management: Chronic and Long-term, Complications and Prognosis - [74]
Pose-Reino A, Runkle de la Vega I, de Jong-Laird A et al.. “Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.” Advances in therapy (2021). PMID: 33306187 ↗
L2bCOHORTCited in: Pathophysiology - [75]
Soleimani M. “Acid base homeostasis and serum bicarbonate concentration in syndrome of inappropriate anti-diuretic hormone secretion (SIADH) with hyponatremia.” Frontiers in endocrinology (2023). PMID: 38144560 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [76]
Moodley N. “Copeptin analysis in endocrine disorders.” Frontiers in endocrinology (2023). PMID: 37859988 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [77]
Warren AM, Grossmann M, Christ-Crain M et al.. “Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management.” Endocrine reviews (2023). PMID: 36974717 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [78]
Dellal FD, Karaahmetli G, Guven SC et al.. “Eosinophilic granulomatosis with polyangiitis as a rare cause of the syndrome of inappropriate antidiuretic hormone secretion.” Irish journal of medical science (2023). PMID: 35895178 ↗
L4CASE_REPORTCited in: Pathophysiology - [79]
Bardanzellu F, Marcialis MA, Frassetto R et al.. “Differential diagnosis between syndrome of inappropriate antidiuretic hormone secretion and cerebral/renal salt wasting syndrome in children over 1 year: proposal for a simple algorithm.” Pediatric nephrology (Berlin, Germany) (2022). PMID: 34468821 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Diagnostic Criteria - [80]
Driano JE, Lteif AN, Creo AL. “Vasopressin-Dependent Disorders: What Is New in Children?” Pediatrics (2021). PMID: 33795481 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [81]
Li W, Teng S, Zhao SY et al.. “Syndrome of Inappropriate Secretion of Antidiuretic Hormone Associated With Varicella Infection in Children.” The Pediatric infectious disease journal (2022). PMID: 35703281 ↗
L4CASE_REPORTCited in: Pathophysiology - [82]
van Bockxmeer JJ, Lau A, Varshney V. “Ketamine-precipitated syndrome of inappropriate antidiuretic hormone secretion in a patient with persistent lumbar pain: a case report.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2022). PMID: 35233721 ↗
L4CASE_REPORTCited in: Pathophysiology, Clinical Features - [83]
Johnson RJ, Lee SMK, Sánchez-Lozada LG et al.. “Fructose: A New Variable to Consider in SIADH and the Hyponatremia Associated With Long-Distance Running?” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 36940740 ↗
L5OTHERCited in: Pathophysiology, Complications and Prognosis, Special Populations - [84]
Jun K, Ah YM, Shin J et al.. “The differential risk of severe hyponatraemia based on the use patterns of hyponatraemia-inducing medications in older adults.” Age and ageing (2023). PMID: 36861184 ↗
L5OTHERCited in: Pathophysiology, Special Populations - [85]
Marroncini G, Anceschi C, Naldi L et al.. “Hyponatremia-related liver steatofibrosis and impaired spermatogenesis: evidence from a mouse model of the syndrome of inappropriate antidiuresis.” Journal of endocrinological investigation (2023). PMID: 36436190 ↗
L5OTHERCited in: Pathophysiology - [86]
Reinke LM, Seoudy AK, Gärtner F et al.. “Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland.” Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (2023). PMID: 37364592 ↗
L4CASE_REPORTCited in: Pathophysiology, Management: Chronic and Long-term - [87]
Moon RJ, Soliman M, Hoogenboom L et al.. “Syndrome of inappropriate secretion of anti-diuretic hormone due to hypothalamic hamartoma: use of tolvaptan.” Journal of pediatric endocrinology & metabolism : JPEM (2023). PMID: 37327191 ↗
L4CASE_REPORTCited in: Pathophysiology, Clinical Features, Management: Chronic and Long-term - [88]
Cui J, Halpin K, Paprocki E. “Urea as safe treatment for hyponatremia due to syndrome of inappropriate antidiuretic hormone in infant with solitary central incisor and neurofibromatosis-1.” Journal of pediatric endocrinology & metabolism : JPEM (2023). PMID: 36420541 ↗
L4CASE_REPORTCited in: Pathophysiology - [89]
Brooks EK, Inder WJ. “Disorders of Salt and Water Balance After Pituitary Surgery.” The Journal of clinical endocrinology and metabolism (2022). PMID: 36300330 ↗
L5OTHERCited in: Pathophysiology - [90]
Tripathi A, Kumar M, Kalita J et al.. “Renin, antidiuretic hormone (ADH), and ADH receptor levels in cerebral salt wasting associated with tuberculous meningitis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022). PMID: 34988719 ↗
L5OTHERCited in: Pathophysiology - [91]
Snyder MH, Asuzu DT, Shaver DE et al.. “Routine postoperative fluid restriction to prevent syndrome of inappropriate antidiuretic hormone secretion after transsphenoidal resection of pituitary adenoma.” Journal of neurosurgery (2022). PMID: 34330096 ↗
L5OTHERCited in: Pathophysiology - [92]
Wang AY, Wong TT, Hsieh KL et al.. “Giant cystic hypothalamic hamartoma in an infant associated with persistent syndrome of inappropriate antidiuretic hormone secretion.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2022). PMID: 35048169 ↗
L4CASE_REPORTCited in: Pathophysiology, Clinical Features - [93]
Hellas JA, Andrew RD. “Neuronal Swelling: A Non-osmotic Consequence of Spreading Depolarization.” Neurocritical care (2021). PMID: 34498208 ↗
L5OTHERCited in: Pathophysiology - [94]
Smale M, Freckelton J, Waters M et al.. “Hyponatraemia due to the syndrome of inappropriate antidiuretic hormone secretion in adults with respiratory syncytial virus infection.” Internal medicine journal (2021). PMID: 34423538 ↗
L4CASE_REPORTCited in: Pathophysiology - [95]
Poch E, Molina A, Piñeiro G. “Syndrome of inappropriate antidiuretic hormone secretion.” Medicina clinica (2022). PMID: 35659417 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [96]
Dong QW, Tang L, Ge DD et al.. “A case of linezolid-induced SIADH in elderly and a review of the literature.” European review for medical and pharmacological sciences (2022). PMID: 36066143 ↗
L4CASE_REPORTCited in: Pathophysiology - [97]
Jamhour C, Haddad A, Daw H. “Severe Hyponatremia During First Cycle of Cyclophosphamide/Doxorubicin Chemotherapy.” American journal of therapeutics (Unknown). PMID: 35584371 ↗
L4CASE_REPORTCited in: Pathophysiology - [98]
Constanthin PE, Isidor N, De Seigneux S et al.. “Urinary oxytocin secretion after pituitary surgery, early arginine vasopressin deficiency and syndrome of inappropriate antidiuresis.” Endocrine (2025). PMID: 39681826 ↗
L5OTHERCited in: Pathophysiology - [99]
Meena AK, Nanda PM, Sharma R et al.. “Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis.” Indian journal of pediatrics (2024). PMID: 36757652 ↗
L5OTHERCited in: Pathophysiology - [100]
Verrienti M, Marino Picciola V, Ambrosio MR et al.. “Pituitary and COVID-19 vaccination: a systematic review.” Pituitary (2024). PMID: 38761322 ↗
L2aSR_OBSCited in: Clinical Features, Management: Acute and Emergency - [101]
Adrogué HJ, Tucker BM, Madias NE. “Diagnosis and Management of Hyponatremia: A Review.” JAMA (2022). PMID: 35852524 ↗
L5REVIEW_NARRATIVECited in: Clinical Features, Management: Acute and Emergency - [102]
Brayo P, Serrano E, Thakkar RS et al.. “Pearls & Oy-sters: Syndrome of Inappropriate Antidiuretic Hormone Secretion Presenting as Neuromyelitis Optica Spectrum Disorder Flare.” Neurology (2023). PMID: 37487758 ↗
L4CASE_REPORTCited in: Clinical Features, Diagnostic Criteria, Management: Acute and Emergency - [103]
Baig MU, Madden K, Moody K. “Hyponatremia with Antidepressant: A Rare Side Effect from Duloxetine in a Child with Acute Leukemia.” Journal of palliative medicine (2022). PMID: 35537479 ↗
L4CASE_REPORTCited in: Clinical Features - [104]
Takenouchi H, Anno T, Kimura Y et al.. “Case Report: A Patient With Neuroleptic Malignant Syndrome, Water Intoxication and Hyponatremia Associated With Severe Cerebral Edema and Coma.” Frontiers in endocrinology (2022). PMID: 35360072 ↗
L4CASE_REPORTCited in: Clinical Features - [105]
Yusuf A, Alhaj O, Aldaheri A et al.. “Rare Coexistence of Acute Intermittent Porphyria With Systemic Lupus Erythematous: Case Report and Literature Review.” Journal of investigative medicine high impact case reports (2023). PMID: 37341437 ↗
L4CASE_REPORTCited in: Clinical Features - [106]
Klimek M, de Smalen P, Janssen J. “Hyperlactatemia and other perioperative metabolic disturbances in neuroanesthesia.” Current opinion in anaesthesiology (2022). PMID: 35942723 ↗
L5REVIEW_NARRATIVECited in: Clinical Features - [107]
Kim J, Scott-Miller R. “Anesthesia for Pituitary Surgery.” Otolaryngologic clinics of North America (2022). PMID: 35365315 ↗
L5REVIEW_NARRATIVECited in: Clinical Features - [108]
Săcărescu A, Turliuc MD, Brănișteanu DD. “Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction.” Neuropeptides (2021). PMID: 34175655 ↗
L5REVIEW_NARRATIVECited in: Clinical Features - [109]
Frara S, Allora A, Castellino L et al.. “COVID-19 and the pituitary.” Pituitary (2021). PMID: 33939057 ↗
L5REVIEW_NARRATIVECited in: Clinical Features, Diagnostic Criteria, Complications and Prognosis - [110]
Gheorghe G, Ilie M, Bungau S et al.. “Is There a Relationship between COVID-19 and Hyponatremia?” Medicina (Kaunas, Lithuania) (2021). PMID: 33435405 ↗
L5REVIEW_NARRATIVECited in: Clinical Features, Complications and Prognosis - [111]
Refardt J, Winzeler B, Christ-Crain M. “Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis.” Clinical endocrinology (2019). PMID: 31004513 ↗
L5REVIEW_NARRATIVECited in: Clinical Features - [112]
Wang D, Lai J, Lu S et al.. “Rapid-onset hyponatremia and delirium following duloxetine treatment for postherpetic neuralgia: Case report and literature review.” Medicine (2018). PMID: 30431592 ↗
L4CASE_REPORTCited in: Clinical Features - [113]
Tseriotis VS, Mitkani C, Lioliou F et al.. “Encephalopathy with cerebellar deficits in a context of hyponatremia.” Acta neurologica Belgica (2024). PMID: 39343832 ↗
L4CASE_REPORTCited in: Clinical Features - [114]
Finsterer J. “Boswellia serrata intoxication manifesting with syndrome of inappropriate antidiuretic hormone secretion, hyponatremia, seizure, and rhabdomyolysis.” Critical care science (2024). PMID: 38922237 ↗
L4CASE_REPORTCited in: Clinical Features - [115]
Findlay MC, Drexler R, Khan M et al.. “A Multicenter, Propensity Score-Matched Assessment of Endoscopic Versus Microscopic Approaches in the Management of Pituitary Adenomas.” Neurosurgery (2023). PMID: 37057921 ↗
L5OTHERCited in: Clinical Features, Diagnostic Criteria, Complications and Prognosis - [116]
Sato A, Yasui-Furukori N, Oda Y et al.. “Asymptomatic syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following duloxetine treatment for pain with depression: Two case reports.” Neuropsychopharmacology reports (2022). PMID: 35733329 ↗
L4CASE_REPORTCited in: Clinical Features, Special Populations - [117]
Kulkarni AG, Das S, Kunder TS. “Are There Differences Between Patients with Extreme Stenosis and Non-extreme Stenosis in Terms of Pain, Function or Complications After Spinal Decompression Using a Tubular Retractor System?” Clinical orthopaedics and related research (2020). PMID: 31633587 ↗
L5OTHERCited in: Clinical Features - [118]
Chakraborty T, Kramer CL, Wijdicks EFM et al.. “Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes.” Neurocritical care (2020). PMID: 31297663 ↗
L5OTHERCited in: Clinical Features - [119]
Picone S, Mondì V, Di Palma F et al.. “Neonatal Encephalopathy and SIADH during RSV Infection.” American journal of perinatology (2019). PMID: 31238369 ↗
L4CASE_REPORTCited in: Clinical Features - [120]
Solomon N, Many A, Orbach R et al.. “Maternal and neonatal hyponatremia during labor: a case series.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2019). PMID: 29526150 ↗
L4CASE_REPORTCited in: Clinical Features - [121]
Tamura T, Taniguchi N, Otsuki K et al.. “[A Case of Consciousness Disorder Induced by the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Cisplatin and 5-Fluorouracil Chemotherapy in a Patient with Tongue Cancer].” Gan to kagaku ryoho. Cancer & chemotherapy (2018). PMID: 30026451 ↗
L4CASE_REPORTCited in: Clinical Features - [122]
Chung JY, Lee CJ, Bong JB et al.. “Neuromyelitis optica spectrum disorder with herpes simplex viral infection presenting with syndrome of inappropriate antidiuretic hormone: A case report.” Medicine (2023). PMID: 37904479 ↗
L4CASE_REPORTCited in: Clinical Features - [123]
Kamel MH, Upadhyay A, Borkan SC. “Intractable hyponatremia complicated by a reset osmostat: a case report.” Journal of medical case reports (2023). PMID: 36639685 ↗
L4CASE_REPORTCited in: Clinical Features - [124]
Chander S, Kumari R, Lohana AC et al.. “Urea to Treat Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Systematic Review and Meta-Analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 39362395 ↗
L2aSR_OBSCited in: Diagnostic Criteria, Differential Diagnosis, Management: Chronic and Long-term, Complications and Prognosis - [125]
Warren AM, Grossmann M, Hoermann R et al.. “Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40720585 ↗
L1bRCTCited in: Diagnostic Criteria, Workup and Laboratory Findings, Differential Diagnosis, Management: Acute and Emergency, Management: Chronic and Long-term, Complications and Prognosis, Special Populations - [126]
Berend K, Heldeweg MLA. “The role of the clinical laboratory in diagnosing hyponatremia disorders.” Critical reviews in clinical laboratory sciences (2025). PMID: 40022565 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Criteria, Differential Diagnosis - [127]
Veligratli F, Alexandrou D, Shah S et al.. “Tolvaptan and urea in paediatric hyponatraemia.” Pediatric nephrology (Berlin, Germany) (2024). PMID: 37466863 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Criteria, Management: Chronic and Long-term, Complications and Prognosis - [128]
Berend K, Duits A, Gans ROB. “Challenging cases of hyponatremia incorrectly interpreted by ChatGPT.” BMC medical education (2025). PMID: 40405178 ↗
L4CASE_REPORTCited in: Diagnostic Criteria, Differential Diagnosis - [129]
Sasidharan Pillai S, Boxerman JL, Groblewski JC et al.. “An adolescent girl with syndrome of inappropriate antidiuretic hormone secretion preceding the diagnosis of olfactory neuroblastoma - a case report.” Frontiers in endocrinology (2024). PMID: 39479268 ↗
L4CASE_REPORTCited in: Diagnostic Criteria, Management: Chronic and Long-term - [130]
Menzi S, Jaramillo SD, Pfister S et al.. “Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH.” Frontiers in endocrinology (2024). PMID: 38803472 ↗
L4CASE_REPORTCited in: Diagnostic Criteria, Differential Diagnosis, Management: Chronic and Long-term, Complications and Prognosis, Special Populations - [131]
Amir M, Renata A, Ratana LT. “Symptomatic sinus bradycardia due to electrolyte imbalances in syndrome of inappropriate antidiuretic hormone (SIADH) related covid-19: a case report.” BMC infectious diseases (2021). PMID: 34020617 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [132]
Sarikonda A, Rafi R, Schuessler C et al.. “Smartphone Applications for Remote Monitoring of Patients After Transsphenoidal Pituitary Surgery: A Narrative Review of Emerging Technologies.” World neurosurgery (2024). PMID: 39214293 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Criteria - [133]
Meng H, Wang J, Hou J et al.. “Case report: Hyponatremia is an initial presentation of Neuromyelitis optica spectrum disorder.” The International journal of neuroscience (2024). PMID: 38019130 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [134]
Naimi B, Duffy A, Garvey E et al.. “Trends in Endoscopic and Microscopic Approaches to Transsphenoidal Pituitary Surgery in the US.” The Laryngoscope (2023). PMID: 37318105 ↗
L5OTHERCited in: Diagnostic Criteria, Complications and Prognosis, Special Populations - [135]
Potasso L, Monnerat S, Refardt J et al.. “Chloride and Potassium Assessment Is a Helpful Tool for Differential Diagnosis of Thiazide-Associated Hyponatremia.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36899489 ↗
L5OTHERCited in: Diagnostic Criteria - [136]
Kaur K, Venkatachalapathi S, Mumtaz M et al.. “Decoding Hyponatremia: A Systematic Review of Diagnostic Pathways and Therapeutic Approaches Applied When Correction Fails.” Cureus (2025). PMID: 41357015 ↗
L2aSR_OBSCited in: Workup and Laboratory Findings, Management: Chronic and Long-term - [137]
Kamran N, Mohammad M. “SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications.” Journal of clinical medicine (2026). PMID: 41899044 ↗
L5REVIEW_NARRATIVECited in: Workup and Laboratory Findings, Management: Chronic and Long-term - [138]
Alindogan A, Joseph R. “Disorders of Sodium.” Endocrinology and metabolism clinics of North America (2026). PMID: 41656034 ↗
L5REVIEW_NARRATIVECited in: Workup and Laboratory Findings, Differential Diagnosis, Complications and Prognosis - [139]
Jiang Z, Qu X, Yan Z et al.. “Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses.” Frontiers in pharmacology (2026). PMID: 41693783 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings - [140]
Nishii M, Shimomura M, Okada S et al.. “Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) by osimertinib and continued treatment with dose reduction for postoperative recurrence of lung adenocarcinoma: a case report.” Translational lung cancer research (2025). PMID: 41132965 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings - [141]
Li J, Yang Z, Wang K et al.. “Syndrome of inappropriate antidiuretic hormone secretion following extensively drug-resistant Klebsiella pneumoniae associated with complicated urinary tract infection: a case report.” Frontiers in medicine (2025). PMID: 40636392 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings, Management: Chronic and Long-term - [142]
Desai S, Holsaeter K, Winski A et al.. “Safety and Efficacy of Tolvaptan for Acute Refractive Hyponatremia Associated with Traumatic Brain Injury.” Journal of clinical medicine (2025). PMID: 40943898 ↗
L5OTHERCited in: Workup and Laboratory Findings, Management: Chronic and Long-term, Complications and Prognosis - [143]
Lee S, Seo HW, Lee J et al.. “Unusual Presentation of Hyponatremia: Persistent Hiccups.” Electrolyte & blood pressure : E & BP (2025). PMID: 41541563 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings, Management: Chronic and Long-term - [144]
Dong C, Zhu B, Miao G et al.. “Case Report: One case of pregnancy complicated by large cell neuroendocrine carcinoma of the cervix with syndrome of inappropriate secretion of antidiuretic hormone.” Frontiers in oncology (2025). PMID: 41395606 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings - [145]
Li X, Xu T, Jian X. “Advanced small cell lung cancer with severe hyponatremia: a case report and literature review.” Frontiers in oncology (2025). PMID: 41018077 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings - [146]
Banerjee S, George A, Bala A et al.. “Assessing the Role of Delta Copeptin in the Evaluation of SIAD and CSW.” Indian journal of pediatrics (2026). PMID: 41563654 ↗
L5OTHERCited in: Workup and Laboratory Findings - [147]
Gil Dos Santos S, Calheiros R, Oliveira J et al.. “Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center.” Clinical endocrinology (2026). PMID: 40993889 ↗
L5OTHERCited in: Workup and Laboratory Findings - [148]
Izquierdo Alarcón B, Castillo Pérez C, Jurado Parras P et al.. “Approach to hyponatremia: the value of fractional excretion of uric acid and phosphate.” Laboratory medicine (2026). PMID: 41886512 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings - [149]
Akgül YSS, Cengiz BE, Akın S. “Rapid-Onset SIADH Triggered by Combined Duloxetine and Levodopa Use in an Older Adult With Depression and Parkinsonism: A Previously Unreported Interaction.” International journal of psychiatry in medicine (2026). PMID: 40859822 ↗
L4CASE_REPORTCited in: Workup and Laboratory Findings - [150]
Yamichannaiah C, Sheth KV, Lila AR et al.. “Management of water and electrolyte disorders post-pituitary adenoma surgery: experience with Tolvaptan 7.5 mg at a tertiary care centre.” Pituitary (2025). PMID: 41148440 ↗
L5OTHERCited in: Workup and Laboratory Findings - [151]
Limongiello MA, Metafuni E, Giammarco S et al.. “High-dose thiotepa may induce inappropriate secretion of antidiuretic hormone syndrome (SIADH) during conditioning treatment for allogeneic stem cell transplantation.” International journal of hematology (2025). PMID: 40660061 ↗
L5OTHERCited in: Workup and Laboratory Findings - [152]
Mussarat A, Stielper Z, Hayden C et al.. “Severe hyponatremia secondary to syndrome of inappropriate antidiuretic hormone (SIADH): A rare cause of takotsubo (stress) cardiomyopathy.” The American journal of the medical sciences (2025). PMID: 39168409 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Special Populations - [153]
Imbriano LJ, Grant C, Masani N. “The Different Paths That Lead to Hypotonic Hyponatremia, and a Safe Approach to Treatment.” Journal of clinical medicine (2024). PMID: 39797178 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [154]
Spasovski G. “Hyponatraemia-treatment standard 2024.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 39009016 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management: Acute and Emergency, Management: Chronic and Long-term - [155]
Netto AB, Chandrahasa N, Koshy SS et al.. “Hyponatremia in Guillain-Barre Syndrome: A Review of Its Pathophysiology and Management.” The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2025). PMID: 38361453 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [156]
Yamagata S, Kageyama K, Yanagimachi M et al.. “Simultaneous Occurrence of Hyponatremia and Hypokalemia in a Patient with Herpes Zoster: A Case Report with a Review of the Literature.” Internal medicine (Tokyo, Japan) (2025). PMID: 38811217 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [157]
Peri A, Naldi L, Norello D et al.. “Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19.” Pituitary (2024). PMID: 39196447 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [158]
Potasso L, Refardt J, Meier C et al.. “Effect of hyponatremia normalization on osteoblast function in patients with SIAD.” European journal of endocrinology (2021). PMID: 34678762 ↗
L1bRCTCited in: Management: Acute and Emergency, Special Populations - [159]
Garrahy A, Galloway I, Hannon AM et al.. “Fluid Restriction Therapy for Chronic SIAD; Results of a Prospective Randomized Controlled Trial.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32879954 ↗
L1bRCTCited in: Management: Acute and Emergency - [160]
Krisanapan P, Vongsanim S, Pin-On P et al.. “Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial).” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 32199708 ↗
L1bRCTCited in: Management: Acute and Emergency, Complications and Prognosis - [161]
Refardt J, Imber C, Sailer CO et al.. “A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.” Journal of the American Society of Nephrology : JASN (2020). PMID: 32019783 ↗
L1bRCTCited in: Management: Acute and Emergency, Complications and Prognosis - [162]
Arima H, Goto K, Motozawa T et al.. “Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.” Endocrine journal (2021). PMID: 32863282 ↗
L2bTRIAL_NONRANDOMCited in: Management: Acute and Emergency, Complications and Prognosis - [163]
Li K, Zhang J, Wang XS et al.. “A systematic review of effects and complications after transsphenoidal pituitary surgery: endoscopic versus microscopic approach.” Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy (2020). PMID: 31495241 ↗
L2aSR_OBSCited in: Management: Acute and Emergency, Complications and Prognosis - [164]
Falhammar H, Skov J, Calissendorff J et al.. “Associations Between Antihypertensive Medications and Severe Hyponatremia: A Swedish Population-Based Case-Control Study.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32285124 ↗
L3bCASE_CONTROLCited in: Management: Acute and Emergency - [165]
Lindner G, Ryser B. “The syndrome of inappropriate antidiuresis after vaccination against COVID-19: case report.” BMC infectious diseases (2021). PMID: 34560836 ↗
L4CASE_REPORTCited in: Management: Acute and Emergency, Special Populations - [166]
Mannheimer B, Falhammar H, Calissendorff J et al.. “Non-thiazide diuretics and hospitalization due to hyponatraemia: A population-based case-control study.” Clinical endocrinology (2021). PMID: 33978246 ↗
L3bCASE_CONTROLCited in: Management: Acute and Emergency - [167]
Falhammar H, Skov J, Calissendorff J et al.. “Inverse association between glucose-lowering medications and severe hyponatremia: a Swedish population-based case-control study.” Endocrine (2020). PMID: 31875925 ↗
L3bCASE_CONTROLCited in: Management: Acute and Emergency - [168]
Gannamani V, Varma A, Nathan S et al.. “Human herpesvirus 6 (HHV-6) associated permanent hyponatremia in umbilical cord blood transplant recipient.” Transplant immunology (2023). PMID: 36372142 ↗
L4CASE_REPORTCited in: Management: Acute and Emergency - [169]
Chen S, Shey J, Chiaramonte R. “Ratio Profile: Physiologic Approach to Estimating Appropriate Intravenous Fluid Rate to Manage Hyponatremia in the Syndrome of Inappropriate Antidiuresis.” Kidney360 (2022). PMID: 36591355 ↗
L5REVIEW_NARRATIVECited in: Management: Acute and Emergency - [170]
Lindner G, Schwarz C, Haidinger M et al.. “Hyponatremia in the emergency department.” The American journal of emergency medicine (2022). PMID: 35870366 ↗
L5REVIEW_NARRATIVECited in: Management: Acute and Emergency - [171]
Ayoola A, Sodji QH, Chin S et al.. “Syndrome of inappropriate secretion of antidiuretic hormone following high dose rate brachytherapy for prostate cancer: a case report.” BMC urology (2022). PMID: 35272646 ↗
L4CASE_REPORTCited in: Management: Acute and Emergency, Special Populations - [172]
Noda Y, Sasaki S. “Updates and Perspectives on Aquaporin-2 and Water Balance Disorders.” International journal of molecular sciences (2021). PMID: 34884753 ↗
L5REVIEW_NARRATIVECited in: Management: Acute and Emergency - [173]
Indirli R, Ferreira de Carvalho J, Cremaschi A et al.. “Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis.” Frontiers in endocrinology (2021). PMID: 34108941 ↗
L5OTHERCited in: Management: Acute and Emergency - [174]
Chifu I, Gerstl A, Lengenfelder B et al.. “Treatment of symptomatic hyponatremia with hypertonic saline: a real-life observational study.” European journal of endocrinology (2021). PMID: 33635825 ↗
L5OTHERCited in: Management: Acute and Emergency - [175]
Rotermund R, Mader MM, Burkhardt T et al.. “Real-life analysis of 280 patients with surgically treated acromegaly: a single-center experience from 2008 to 2015.” Neurosurgical focus (2020). PMID: 32480363 ↗
L5OTHERCited in: Management: Acute and Emergency - [176]
Monnerat S, Atila C, Baur F et al.. “Effect of protein supplementation on plasma sodium levels in the syndrome of inappropriate antidiuresis: a monocentric, open-label, proof-of-concept study-the TREASURE study.” European journal of endocrinology (2023). PMID: 37540987 ↗
L2bTRIAL_NONRANDOMCited in: Management: Chronic and Long-term - [177]
Hagiwara D, Matsukawa M, Tasaki J et al.. “A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.” Endocrine journal (2023). PMID: 37914256 ↗
L2bCOHORTCited in: Management: Chronic and Long-term - [178]
Arecco A, Demontis D, Della Sala L et al.. “Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD.” Frontiers in endocrinology (2023). PMID: 38288467 ↗
L4CASE_REPORTCited in: Management: Chronic and Long-term - [179]
Wu J, Yan Z, Li B et al.. “Pituitary Apoplexy-associated Cerebral Salt Wasting Syndrome: A Case Report and Literature Review.” Clinical therapeutics (2023). PMID: 37778916 ↗
L4CASE_REPORTCited in: Management: Chronic and Long-term - [180]
Li N, Zhang H, Wang S et al.. “Urea transporter UT-A1 as a novel drug target for hyponatremia.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024). PMID: 38924449 ↗
L5OTHERCited in: Management: Chronic and Long-term - [181]
Gadoth A, Nisnboym M, Alcalay Y et al.. “Electrolyte Imbalance in Anti-LGI1 Encephalitis: It Is Not All in Your Head.” Neurology(R) neuroimmunology & neuroinflammation (2023). PMID: 37591767 ↗
L5REVIEW_NARRATIVECited in: Management: Chronic and Long-term, Special Populations - [182]
Seay NW, Lehrich RW, Greenberg A. “Diagnosis and Management of Disorders of Body Tonicity-Hyponatremia and Hypernatremia: Core Curriculum 2020.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 31606238 ↗
L5REVIEW_NARRATIVECited in: Complications and Prognosis - [183]
Alindogan A, Joseph R. “Disorders of Sodium.” Emergency medicine clinics of North America (2023). PMID: 37758418 ↗
L5REVIEW_NARRATIVECited in: Complications and Prognosis - [184]
Li C, Zhu H, Zong X et al.. “Experience of trans-nasal endoscopic surgery for pituitary tumors in a single center in China: Surgical results in a cohort of 2032 patients, operated between 2006 and 2018.” Clinical neurology and neurosurgery (2020). PMID: 32905978 ↗
L5REVIEW_NARRATIVECited in: Complications and Prognosis - [185]
Decaux G. “Morbidity Associated with Chronic Hyponatremia.” Journal of clinical medicine (2023). PMID: 36769626 ↗
L5OTHERCited in: Complications and Prognosis - [186]
Ye Q, Peng X, Zhang X et al.. “Clinical analysis of 103 cases of tuberculous meningitis complicated with hyponatremia in adults.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022). PMID: 34510291 ↗
L5OTHERCited in: Complications and Prognosis - [187]
Abufaraj M, Ramadan R, Alkhatib A. “Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review.” Current oncology (Toronto, Ont.) (2024). PMID: 38534956 ↗
L2aSR_OBSCited in: Special Populations - [188]
Bioletto F, Varaldo E, Prencipe N et al.. “Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review.” Hormones (Athens, Greece) (2023). PMID: 36656532 ↗
L4CASE_REPORTCited in: Special Populations - [189]
Yang F, Cao Z, Wang X et al.. “A multi-parameter study of the etiological diagnosis of hyponatremia after hypothalamic tumor surgery.” Clinical neurology and neurosurgery (2021). PMID: 34715556 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [190]
Sasaki T, Shindo Y, Kikuchi K et al.. “Vortioxetine-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report.” Neuropsychopharmacology reports (2024). PMID: 38588007 ↗
L4CASE_REPORTCited in: Special Populations - [191]
Pazos-Guerra M, Ruiz-Sánchez JG, Pérez-Candel X et al.. “Inappropriate therapy of euvolemic hyponatremia, the most frequent type of hyponatremia in SARS-CoV-2 infection, is associated with increased mortality in COVID-19 patients.” Frontiers in endocrinology (2023). PMID: 37560297 ↗
L5OTHERCited in: Special Populations - [192]
Estilo A, McCormick L, Rahman M. “Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.” Advances in therapy (2021). PMID: 34693505 ↗
L5OTHERCited in: Special Populations - [193]
Spasovski G, Vanholder R, Allolio B et al.. “Clinical practice guideline on diagnosis and treatment of hyponatraemia.” European journal of endocrinology (2014). PMID: 24569125 ↗
L1cGUIDELINECited in: Guidelines and Resources - [194]
Spasovski G, Vanholder R, Allolio B et al.. “Clinical practice guideline on diagnosis and treatment of hyponatraemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2014). PMID: 24569496 ↗
L1cGUIDELINECited in: Guidelines and Resources - [195]
Bennett BL, Hew-Butler T, Hoffman MD et al.. “Wilderness Medical Society practice guidelines for treatment of exercise-associated hyponatremia: 2014 update.” Wilderness & environmental medicine (2014). PMID: 25498260 ↗
L1cGUIDELINECited in: Guidelines and Resources - [196]
Runkle I, Villabona C, Navarro A et al.. “[The treament of hyponatremia secundary to the syndrome of inappropriate antidiuretic hormone secretion].” Medicina clinica (2013). PMID: 24169317 ↗
L1cGUIDELINECited in: Guidelines and Resources - [197]
Bennett BL, Hew-Butler T, Hoffman MD et al.. “Wilderness Medical Society practice guidelines for treatment of exercise-associated hyponatremia.” Wilderness & environmental medicine (2013). PMID: 23590928 ↗
L1cGUIDELINECited in: Guidelines and Resources - [198]
Lamas C, del Pozo C, Villabona C. “Clinical guidelines for management of diabetes insipidus and syndrome of inappropriate antidiuretic hormone secretion after pituitary surgery.” Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion (2014). PMID: 24588923 ↗
L1cGUIDELINECited in: Guidelines and Resources